Medical immunology: a new journal for a new subspecialty by unknown
BioMed CentralMedical Immunology
ssOpen AcceMedical Immunology 2002, 1 xEditorial
Medical immunology: a new journal for a new subspecialty
Kendall A Smith
Address: The Division of Immunology, Department of Medicine Weill Medical, College of Cornell University, 1300 York Avenue, Box 41, New 
York, NY 10021, USA
E-mail: kasmith@med.cornell.edu
This new journal, Medical Immunology, was conceived to
fill the large divide between the science of basic immunol-
ogy and the application of this scientific knowledge to the
diagnosis, treatment and prevention of diseases of the im-
mune system. Why is there a gap between the basic science
of immunology and the application of this science to
medicine? The answers to this question are historical in
large part, in that the immune system has only become
recognized and defined within the last century. Moreover,
the rate of accumulation of new information has acceler-
ated markedly, with most of our present understanding
acquired only within the past 20 years. Consequently,
most of what we know about the immune system has only
come into being within the professional lifetimes of the
practicing medical community. Because of this recent ex-
plosion in knowledge, there simply has not been enough
time for the translation to clinical medicine to occur.
There is a large community of basic scientists who have
been educated in the last few decades and who have con-
tributed to the current state of knowledge in immunology.
By comparison, because of "turf" concerns amongst facul-
ties of medical schools, immunology course time in med-
ical schools has been miniscule if covered in the
curriculum at all. Consequently, most practitioners have
not received much formal education in immunology. My
medical colleagues often tell me that the immunological
acronyms and jargon are huge and obfuscating, and they
have no idea what the immunologists are talking about.
There is definitely a gap between the immunologists and
the clinicians.
Even so, because of the rapid advances that have been
made, especially within the last 20 years, we now have a
new understanding of how the immune system functions,
and we have available to us many new molecules to use as
therapeutics. As well, because of advances in molecular
genetics, we now have the capacity to engineer new mole-
cules and vaccines at will. Consequently, there is now a
tremendous need for clinical research to determine how
best to use these new therapeutics, particularly, without
toxicity.
Because the modern science of immunology has only
sprouted within the last 2–3 decades, most of those who
contributed to our present view of the immune system are
alive and well and still contributing. Therefore, by taking
an historical view on this newest "organ system", it is eas-
iest to gain an appreciation of what we now know, by fo-
cusing on those who have made a significant impact on
medical immunology. As well, such a review should serve
to illuminate those areas that promise to be the most fruit-
ful areas for future development.
The discovery of the immune system and the 
dashed hopes of our medical immunologist fore-
fathers
Immunology is the study of the physiology of the im-
mune system, while the pathophysiology of the immune
system is not of concern to many immunologists. Claude
Published: 30 September 2002
Medical Immunology 2002, 1:1
Received: 29 September 2002
Accepted: 30 September 2002
This article is available from: http://www.medimmunol.com/content/1/1/1
© 2002 Smith; licensee BioMed Central Ltd. This article is published in Open Access: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.Page 1 of 17
(page number not for citation purposes)
Medical Immunology  2002, 1 http://www.medimmunol.com/content/1/1/1Bernard made the connection between the physiology
and pathophysiology of organ systems in his book, "An
Introduction to Experimental Medicine", which was first
published in 1865 [1]. At that time, the immune system
had not yet been discovered, while the circulatory system,
for example, had been scrutinized for 300 years. Sir Ed-
ward Jenner had opened the way to the immune system in
1798 with his description of cowpox virus vaccination
against smallpox [2]. However, for most of the 19th centu-
ry this phenomenon was considered a special case, and
not applicable to other diseases. Microbes had yet to be
understood as the causes of contagious diseases.
Louis Pasteur forwarded the germ theory in 1857 to coun-
ter the popular concept of "spontaneous generation" as
responsible for fermentation. However 20 years passed
before Robert Koch first proved that microbes could actu-
ally be responsible for causing disease in his seminal stud-
ies on anthrax [3]. This demonstration set the stage for
Pasteur to introduce and promote the idea that it might be
possible to attenuate microbes, which could then be used
to prevent microbial infections by vaccination [4–6]. At
about the same time, Eli Metchnikoff discovered phagocy-
tosis, thereby introducing the concept that the host has
cellular defenses against invasion by microbes [7]. Then,
in 1890 with the discovery by Behring and Kitasato of an-
tibody activity against diphtheria and tetanus toxins [8],
serotherapy was soon initiated for these and other dread
bacterial infections and found to be quite effective. Ac-
cordingly, 100 years ago at the beginning of the 20th cen-
tury it was hoped that it would not only be possible to
prevent infections by vaccination, but to also treat them
effectively with antibodies. Medical immunology was
born.
However, the attenuation of microbes proved elusive, as
each microbe was found to be complicated and distinct.
As well, Charles Richet and Paul Portier soon discovered
anaphylaxis [9]. Thus, there appeared to be a downside to
the repetitive injection of foreign molecules and mi-
crobes, and prophylaxis by vaccination was not so easily
attained. Moreover, even though serotherapy was effective
and many of those treated recovered from dread diseases
such as diphtheria and scarlet fever, it was soon discov-
ered by Arthus that the horse sera used for the serothera-
pies could produce an inflammatory syndrome itself [10],
which was dubbed "Serum Sickness" by Clemmons von
Pirquet and Bela Shick [11]. Also, at the same time, Wil-
liam Coley introduced the injection of bacterial extracts
(Coley's toxins) as therapy for cancer [12]. Even though
curative in some cases, Coley's toxins were never widely
accepted because of the severity of the reactions induced.
Accordingly, it was realized that a good deal more knowl-
edge was going to be necessary before the power of the im-
mune system could be harnessed, and the hopes of
physicians regarding the promise of manipulating the im-
mune system for the prevention and treatment of disease
faded.
The first half of the 20th century: understanding 
antibodies and bacteria
With the demise of immunotherapy the science of immu-
nology was born at the beginning of the 20th century. For
the next 50 years those interested in the immune system
focused on trying to understand the physiology of the sys-
tem. During this time, the focus was almost entirely on
understanding the function and structure of antibodies,
and the cellular immunology of Metchnikoff was forgot-
ten. Karl Landsteiner's work stands out among the many
contributors to our knowledge of serology, because he
showed that antibodies are both tremendously diverse,
capable of binding to almost all environmental mole-
cules, and also exquisitely specific [13].
Simultaneously, in the first half of the 20th century the sci-
ence of bacteriology was born and basic scientists com-
menced with the painstaking laboratory research
characterizing these diverse microbes. By the 1950s, most
bacteria had been identified, categorized, and character-
ized thoroughly. Then, with the advent of antibiotics,
many bacterial diseases could finally be treated effectively.
Also, antibiotics made extended cell cultures feasible for
the first time, which were instrumental for both the dis-
covery and propagation of viruses, so necessary for the cre-
ation of attenuated live viral vaccines. Only then, was
Pasteur's dream of vaccines finally realized, and then only
for viral infections. Moreover, the first successful vaccines
for poliovirus and the other childhood exanthems were
developed empirically, without knowledge as to how the
immune system actually works. Consequently, immunol-
ogy as a basic science had to develop before the applica-
tion of this new knowledge to immunological diseases
could occur.
Identifying the cells of the immune system
The advances in cell culture methods also led to the culti-
vation of lymphocytes, and the discovery by Peter Nowell
in 1960 that lymphocytes were not end-stage differentiat-
ed cells as had been thought, but rather they were capable
of rapid and extensive proliferation in response to mi-
togens and antigens [14]. As well, plasma cells, which by
then were known to the source of antibodies [15], actually
were shown to be derived from lymphocytes. Soon there-
after, Neils Jerne and Al Nordin developed an assay that
could detect individual spleen cells as antibody producers
[16], which essentially proved Sir McFarland Burnett's
clonal selection hypothesis of antibody formation [17].Page 2 of 17
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Raff and Pernis as precursors to plasma cells and charac-
terized for the first time as cells with immunoglobulin (Ig)
on their surface [18,19]. Soon thereafter T-lymphocytes (T
cells) were identified for the first time by Raff and Pierre
Vassali's group as lymphocytes lacking surface Ig, but hav-
ing cell surface molecules distinct from B cells [20,21].
Within a few years, dendritic cells (DCs) were described
by Steinman and Cohn as cells morphologically distinct
from Metchnikoff's macrophages and microphages [22].
Natural Killer (NK) cells, which could kill target cells with-
out activation by antigen, were discovered by Herberman
and Keissling, Klein and Wigzell to be a distinct type of
lymphocyte [23,24]. Thus, by the mid 1970s the major
cells responsible for the immune response had been iden-
tified.
Histocompatibility restriction of the immune re-
sponse
In 1959, Benacerraf and Gell showed that cell-mediated
immune reactivity could be detected by using denatured
proteins, while antibody reactivity could not [25,26].
Then, pioneering experiments by Benacerraf's group in the
guinea pig in the early 1960s revealed a genetic compo-
nent to the antibody response to synthetic polypeptide
antigens [27,28]. Subsequently, McDevitt's group con-
firmed and extended these early findings to mice and
showed that the immune responsiveness mapped to the
major histocompatibility complex (MHC) gene loci
[29,30].
Then, in the early 1970s histocompatibility between T
cells and B cells was first found to be necessary for the an-
tigen activation of antibody production by Katz,
Hamaoka and Benacerraff [31], as well as between T cells
and macrophages for the activation of antigen-specific T
cell proliferation by Rosenthal and Shevach [32], and be-
tween virus-infected target cells and cytolytic T cells (CTL)
for the cytolytic reaction by Zinkernagel and Doherty [33].
At the time, the molecular basis for this "histocompatibil-
ity restriction" of antigen recognition was not obvious,
but the idea that antigens somehow could only activate T
cells in the context of autologous molecules encoded by
the MHC entered immunology for the first time.
Cloned antibodies and cloned antibody genes
There followed in 1975 the creation of plasmacytoma/B-
cell hybrids (hybridomas), which produced monoclonal
antibodies by Kohler and Milstein [34]. With the advent
of monoclonal antibodies, the hope of "serotherapy" was
rejuvenated. Thus, scientists as well as the business world
had dreams of "magic bullets" that would target many in-
tractable diseases, such as cancer. However, hybridomas
could not be generated using human cells and the Human
Anti-Mouse Antibody (HAMA) response that was induced
with the mouse antibody treatment was reminiscent of
"Serum Sickness" instead.
In 1976, Hozumi and Tonegawa reported the amazing
findings that revealed how the tremendous diversity of
antibody molecules is generated: genes were found to re-
arrange and recombine [35]. This startling discovery set in
motion a flurry of research that culminated in cloning of
cDNA encoding immunoglobulin chains and ultimately
the cloning of immunoglobulin genes by Tonegawa's
group and Phil Leder's group [36–38]. Accordingly, al-
most a century of science was necessary to finally solve the
mystery of the tremendous diversity but exquisite specifi-
city of antibody molecules.
The advances contributed by many investigators in the 25
years since the initial identification of the immunoglobu-
lin genes, have culminated in the ability to "humanize"
mouse monoclonal antibodies by replacing most of the
mouse gene sequences with human gene sequences. This
manipulation considerably reduces the incidence of
HAMA responses when the antibodies are used therapeu-
tically. In addition, because of advances in molecular ge-
netics, it is now possible to replace mouse
immunoglobulin genes with human genes in embryonic
stem cells, so that mice that produce human antibodies
can be made [39,40]. Since the immune systems of these
mice recognize as foreign everything that is "non-mouse",
it is now possible to generate human monoclonal anti-
bodies reactive with any and all human molecules and
cells. The therapeutic potential of these antibodies is enor-
mous, so that the dreams of the medical immunologists of
a century ago may now finally be realized.
The flow cytometer and CDs
The combination of fluorochrome-conjugated mono-
clonal antibodies with the timely invention of the flow cy-
tometer/Fluorescence-activated cell sorter (FACS) by Len
Herzenberg and his colleagues revolutionized immunolo-
gy [41]. For the first time, large numbers of individual
cells within a population of mononuclear cells from
blood, or spleen and lymph nodes could be identified and
separated. Stuart Schlossman together with Ellis Reinherz
and Jerry Ritz and their colleagues reported that mono-
clonal antibodies could be used to identify functional
subsets of lymphocytes and leukemia cells [42–44], and
they promoted cooperative efforts that led many investi-
gators over the course of the next decade to identify hun-
dreds of monoclonal antibodies that react with cell
surface molecules or Clusters of Determinants (CD) that
detect and discriminate separate lymphocyte subsets and
functions. It is now routine to send blood to the clinical
lab to determine the differential count of CD3+ T cells
(both CD4+ and CD8+ subsets) [44,45], B cells (CD20+)
[46], NK cells (CD16/56+) [47] and monocytes (CD14+)Page 3 of 17
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some of the first lymphocyte subset-specific monoclonal
antibodies reported.
Cloned T cells, cloned T cell antigen receptors 
(TCR) and cloned TCR Genes
In 1979 we reported the creation of the first monoclonal
T cells [49]. Using lymphocyte conditioned media that
Morgan and coworkers had found could promote long-
term T cell growth [50], we had already generated the first
antigen-specific cytolytic T lymphocyte lines (CTLL) by
immunizing mice with allogeneic tumor cells [51]. Subse-
quently, upon limiting dilution cloning, we could show
unequivocally that monoclonal T cells were reactive either
with tumor-specific antigens or alloantigens [49]. At the
time we speculated that monoclonal antigen-specific CTL
might be used as therapy [52]. The generation of T cell
clones that retained antigen-specific function reduced to
the progeny of a single cell the tremendous diversity of T
cell antigen recognition encountered when studying cell
populations isolated from the blood or spleen. Conse-
quently, this breakthrough quickly led to the unequivocal
demonstration of MHC restriction of antigen recognition
by Schwartz and coworkers [53].
Moreover, monoclonal antibodies reactive with T cell
clones led to the discovery of the elusive T cell antigen re-
ceptor (TCR). In 1982, Allison and his co-workers report-
ed the generation of monoclonal antibodies reactive with
a T lymphoma cell line [54]. They speculated that the an-
tibodies recognized a tumor-specific antigen, or perhaps
the TCR. However, they had no way of testing the antibod-
ies to prove their suspicions. Thus, the generation of
"clonotypic" monoclonal antibodies reactive with IL2-de-
pendent normal antigen-specific cytolytic T cell clones en-
abled Reinherz and co-workers in 1983 to identify the first
human TCR [55,56]: their clonotypic monoclonal anti-
bodies blocked antigen-specific activation of the cloned
cytolytic T cells.
As well, Kappler and Marrack and their co-workers identi-
fied the murine TCR by generating clonotypic mono-
clonal antibodies reactive with an antigen-specific T cell
hybridoma. These clonotypic antibodies were agonistic,
and stimulated IL2 production, a TCR-specific functional
assay [57]. Then, all three groups concurred simultane-
ously on their very similar findings, which indicated that
there were both variable and constant portions to the TCR
molecules they had identified on T lymphoma cells, T cell
hybridomas and normal T cell clones [58–60].
Subsequently, in 1984 Hedrick and Davis applied classi-
cal nucleic acid hybridization kinetics and subtractive hy-
bridization to search for the TCR genes, and cloned the
cDNA encoding the first of the TCR chains, which re-
vealed that the TCR genes and molecules belong to the
immunoglobulin super family [61].
Cloned NK cells
Soon after we had reported the first T cell clones, Gunther
Dennert also used lymphocyte conditioned media to de-
rive the first murine NK cell lines and clones, which al-
lowed an unequivocal distinction to be made between
these unique lymphocytes vs. T cells and B cells [62,63].
There followed the derivation of the first human NK cell
lines and clones by Jerry Ritz and his colleagues [64,65],
which enabled them to derive NK cell-specific mono-
clonal antibodies that could be used to distinguish these
cells in a mixed population for the first time [65]. Subse-
quent studies with these NK cell clones revealed that NK
cells produce a restricted set of cytokines that activate
macrophages and DCs (see below). Therefore, innate im-
mune reactivity would eventually be understood to re-
volve around a synergistic interaction between NK cells,
macrophages and DCs (see below).
The interleukins: the hormones of the immune 
system
Although it was possible to culture T cell and NK cell
clones using lymphocyte conditioned media as a source of
growth factor(s), the identity of the molecules in the con-
ditioned media responsible for the growth promoting ac-
tivity remained obscure. Therefore, we used monoclonal T
cells to construct an assay for the T cell growth factor
(TCGF) activity in mitogen-activated lymphocyte condi-
tioned media [66], which enabled the identification and
discrimination of the first hormones of the immune sys-
tem, interleukin-1 (IL1) and interleukin-2 (IL2) [67]. IL1,
a product of activated macrophages originally termed
Lymphocyte activating factor (LAF) [68], was found to
augment the production of TCGF by T cells, hence the nu-
merical order of these first two interleukins [57].
Over the next two decades many additional cytokines
were discovered and found to be responsible for the regu-
lation of the maturation, proliferation, differentiation and
survival of B cells, T cells, NK cells, macrophages and den-
dritic cells [69–74]. The numbering of interleukins now
includes IL27 and promises to continue. Some of the most
important of these interleukins include IL4, initially de-
scribed by simultaneously by Vitteta and Krammer, and
Howard and Paul and their colleagues, which serves as a
growth and differentiation factor for B cells and promotes
the differentiation of monocytes to DCs [69,70], IL7, dis-
covered by Namen,s group, which is a primary growth and
differentiation factor for immature T cell and B cell pro-
genitors [74], IL10, first described by Moore and cowork-
ers, which serves as an important differentiation factor for
B cells and regulates both T cell and dendritic cell function
[75,76], IL12, discovered by Gately and Trinchieri andPage 4 of 17
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entiation factor for cytolytic T cells and NK cells, and pro-
motes the production of IFN- by NK cells and T helper-1
cells [73,76], and IL15, first described by groups led by
Waldmann and and Grabstein, and which promotes the
maturation of NK cells and the survival of memory CTLs
[77,78]. IFN- is an important differentiation factor for
both T cells and B cells, as well as macrophages and den-
dritic cells [79]. In addition, Granulocyte-Macrophage
Colony Stimulating Factor (GM-CSF) described by Met-
calf's team [80,81] promotes the proliferation and differ-
entiation of macrophages and dendritic cells (DCs) from
bone marrow myeloid precursors and blood monocytes
[82].
The generation of the first monoclonal antibodies reactive
with IL2 allowed its purification to homogeneity in milli-
gram quantities in a single step, which was a first in cy-
tokine research [83]. As each cytokine was discovered,
monoclonal antibodies reactive with them aided their pu-
rification as well as detection using ELISA [84], which im-
proved the analysis of cytokine physiology immensely.
However, the development of a flow cytometry assay by
O'Gara's group [85] that allows detection of cytokines
within single cells via cytokine-reactive fluorochrome-
conjugated monoclonal antibodies provided a quantum
jump in the detection of antigen-specific T cells. The key
technical improvement proved to be the addition of in-
hibitors of secretion such as monensin or Brefeldin A,
which allow the accumulation of the cytokines inside the
cells. The power of the single cell analysis of flow cytome-
try, combined with the capacity to examine intracellular
as well as extracellular molecules has thus extended the
analytical capability of the flow cytometer enormously.
Beutler, Cerami and their co-workers showed that pro-in-
flammatory cytokines such as cachectin or tumor necrosis
factor-alpha (TNF-), IL1 and IL6 produced by both lym-
phocytes and macrophages are the "endogenous pyro-
gens" that had led to so much toxicity from Coley's toxins,
and to septic shock from bacteremia [86–89]. Based upon
these findings, Marc Feldmann and his colleagues pains-
takingly developed the concept that inhibition of TNF-
activity would suppress downstream IL1 and IL6 produc-
tion and the chronic inflammation of rheumatoid arthri-
tis [90,91]. Most investigators at the time felt that the pro-
inflammatory cytokines were redundant, so that blocking
only one of them would have little effect. However, sub-
sequently, they showed that humanized monoclonal an-
tibodies reactive with TNF- are effective in suppressing
the inflammation and destruction of rheumatoid arthritis
(RA) [92], while others found them effective in the treat-
ment of inflammatory bowel disease [93].
Studies of T cell clones and the cytokines they produced
also led to the discovery of two distinct types of cytokine-
producing "helper" T cell clones by Mosmann and Coff-
man and their co-workers [94], which regulate the differ-
entiation of B cells (Th-2 cells) [95], as well as T cells (Th-
1 cells) [96]. Subsequently, Swain's [97,98] and Paul's
[99] groups showed that the differentiation of a Th cell to
a Th-2 cell was dependent upon the cytokine milieu. Thus,
IL4 was found to be an important trophic cytokine, pro-
moting the differentiation of Th-2 cells, which secrete
high amounts of IL4, IL5, IL6 and IL10, all cytokines that
influence the differentiation of B cells to antibody produc-
ing plasma cells.
By comparison, O'Gara, Murphy and co-workers found
that IFN- influences Th cells to further secrete IFN-,
thereby favoring activation of macrophages and delayed-
type hypersensitivity. Furthermore, IL12 produced by
IFN--stimulated macrophages and DCs promotes Th-1
differentiation to high IFN- production, so that there is a
reciprocal relationship between Th-1 cells and macro-
phages and DCs, with each favoring the other [100,101].
Pat Bucy and coworkers have examined the expression of
cytokine genes using in situ hybridization and have found
evidence for heterogeneity, consistent with the interpreta-
tion that there is not coordinate regulation of cytokine
genes, and that each cell expresses a restricted repertoire of
cytokine genes in a quantal manner [102]. More recent ex-
periments reported from Glimcher's, Rao's and Murphy's
groups have revealed that this regulation of gene expres-
sion is dependent upon newly discovered transcription
factors and response elements [103–105]. Thus, it appears
that the differentiation of Th cells depends upon the types
and concentrations of cytokines that the cells are exposed
to, which activate specific transcription factors and make
the regulatory sites accessible.
T cell clones were also instrumental in the analysis of cy-
tolytic granules [106] and the isolation of perforin, one of
the active lytic molecules responsible for CTL activity by
Podack and coworkers [107]. Therefore, the complex ef-
fector mechanisms of T cells became to be understood at
the molecular level for the first time. These advances have
spurred the hope that antigen-specific cytolytic T cells
might be used for specific cellular therapy of cancer and
infectious diseases. Actually, Riddell working with Green-
berg's team has shown that cultured monoclonal cytolytic
T cells are effective in the treatment of infection by cy-
tomegalovirus (CMV) [108], while O'Reilly's group have
pioneered the use of T cell clones for the treatment of Ep-
stein-Bar Virus-induced T cell lymphoma [109]. Moreo-
ver, recently Yee and Greenberg and their coworkers have
demonstrated that cloned T cells specific for antigens ex-
pressed by normal melanocytes and malignant melanoma
cells are active in killing both cell types in vivo [110], andPage 5 of 17
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tions [111]. Now that it is possible to identify the T cell
clones after transfer in vivo using the new assays to detect
antigen-specific cells [112], this area will undoubtedly see
a great deal of activity in the future, using T cell clones to
treat both viral infections and tumors.
The identification of the interleukins and pro-inflamma-
tory cytokines led to the isolation of cDNA and genomic
DNA clones encoding each molecule, which enabled the
production of large quantities of recombinant proteins,
thereby greatly facilitating research into the physiology of
cytokines. Taniguchi first cloned the cDNA encoding IL2
[113], thereby showing the way toward cloning all of the
subsequent cytokine molecules. As a result, recombinant
cytokines have now become available for use therapeuti-
cally. Since IL2 was the first recombinant cytokine availa-
ble, it was the first to be used in the clinic. Steven
Rosenberg and Michael Lotze and their team adminis-
tered IL2 in high doses to cancer patients, which resulted
in the signs and symptoms of septic shock or SIRS, remi-
niscent of Coley's toxins [114]. However, like Coley's pa-
tients, some of those treated with high dose IL2, ~5%,
appear to have been cured [115]. We have developed a dif-
ferent approach based on the high affinity of the IL2 re-
ceptor (IL2R) (see below), pharmacokinetic studies, and
experiments by Doreen Cantrell, which showed that the
magnitude of the IL2 biological response is dependent
upon the IL2 concentration, the IL2R density and the du-
ration of the IL2/IL2R interaction [116]. We administer
100-fold lower doses of IL2 continuously by daily subcu-
taneous injections without systemic toxicity [117,118].
Cytokine receptors
The discovery of cytokines also led to the discovery of cy-
tokine receptors. Over the course of the 1980s and 1990s,
the molecules responsible for binding the cytokines and
for signaling the cell were identified and the genes encod-
ing these molecules were cloned. The IL2R was prototypic,
and was found to have a very high affinity (Kd = 10-11 M)
of binding and that the IL2 concentrations that bind to
the receptor are identical to those that promote the bio-
logical response [119]. Initially we used radiolabeled IL2
in classic hormone/receptor binding experiments to dem-
onstrate the IL2R. This assay was then used to identify the
three chains of the receptor responsible for formation of
the high affinity IL2 binding site [120–123]. Subsequent-
ly, these same methods were used to discover each addi-
tional cytokine receptor, as the cytokines became known.
Waldmann's group championed the development of hu-
manized monoclonal antibodies reactive with the -chain
of the IL2R for the suppression of allograft rejection [124],
which have now been shown to be effective in suppressing
rejection of both renal [125] and cardiac allografts [126].
Moreover, soluble TNF- R-Ig chimeric molecules have
also been found efficacious in RA [127]. Thus, blocking
cytokine activities with either monoclonal antibodies or
soluble cytokine receptors promises to be an active area in
medical immunology.
All of the work in the discovery of cytokine receptor
chains recently has resulted in the first successful gene
therapy experiment. Soon after Sugamura's group discov-
ered and cloned the -chain of the IL2R [128], Leonard's
group mapped the gene encoding this chain to the X chro-
mosome and showed that there were mutations in this
gene in patients suffering from X-linked Severe Combined
Immundeficiency (SCID) [129]. Subsequent work re-
vealed that this IL2R chain is also a component of the re-
ceptors for IL4, IL7, IL9, IL13 and IL15, so that this chain
has become known as the common  chain (c) [130].
Then, Alain Fischer's group successfully circumvented the
genetic immunodeficiency using retrovirus transferred c
cDNA into bone marrow stem cells [131].
Signaling the cells
The discovery of the antigen receptors and the cytokine re-
ceptors initiated a quest still ongoing to identify the intra-
cellular signaling molecules and the transcription factors
activated by the triggered receptors. In this search, many
of the immunosuppressive drugs already known were
found to block specific signaling molecules and transcrip-
tion factors activated in lymphocytes and macrophages.
For example, glucocorticoids have been the mainstay of
immunosuppressive and anti-inflammatory therapies for
the past 50 years. Our early experiments revealed that glu-
cocorticoids inhibit the TCR activation of IL2 production
[132]. Subsequent work by both Michael Karin's and Al
Baldwin's groups showed that glucocorticoids block the
TCR activation of Activating Protein-1 (AP-1) and the Nu-
clear Factor-kappa of B cells (NF-B) [133–135]. Similar-
ly, Hermann Wagner and his co-workers showed that the
immunosuppressive antibiotic cyclosporin-A (CSA) is ef-
fective because it also blocks the TCR signaling of cytokine
production [136], and subsequently, Gerald Crabtree's
group found that CSA inhibits the TCR activation of the
Nuclear Factor of Activated T cells (NF-AT) [137].
Subsequent work using gene-deleted mice by Gerondakis'
and Hsiou-Chi Liou's groups have shown that c-Rel,
which is the only member of the NF-B transcription fac-
tor family restricted to the hematopoietic system, is oblig-
atory for TCR and BCR signaling of cytokine gene
expression, proliferation, differentiation and cellular sur-
vival [138–142]. Thus, NF-B, originally described by Sen
and Baltimore as involved in Ig gene expression [143], has
proven to be one of the most important transcriptional ac-
tivating factor families in the immune system and is oblig-Page 6 of 17
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macrophages and dendritic cells.
All of these data underscore the importance of targeting
these signaling molecules and transcription factors for the
development of new traditional small molecule drugs ca-
pable of either suppressing or enhancing immune respon-
siveness. Recently, the power of our new knowledge in
designing effective immunosuppressive regimens was
demonstrated in the combination of the drug FK506,
which like CSA blocks NF-AT activation and thereby IL2
gene expression, with the monoclonal antibody reactive
with the -chain of the IL2R thereby competing for ligand
activation of the IL2R, and Rapamycin, a drug that blocks
IL2/IL2R signaling. This is the first immunosuppressive
combination therapy that has avoided using glucocorti-
coids (which are diabetogenic), and it has been found ef-
fective in preventing rejection of pancreatic islet -cell
grafts as a new therapy for Type I diabetes [144].
Signaling via the interferon receptors and the interleukin
receptors involve some pathways in common with the
TCR and BCR, but a whole new series of molecules were
discovered as critical for cytokine signaling that are not
triggered via the antigen receptors. Experiments focused
on signaling via interferons by Darnell revealed a family
of molecules that upon triggering via interferon were
found to translocate to the nucleus and regulate gene ex-
pression [145]. Subsequently, extensive work by Darnell's
group with elegant genetic experiments by Stark and Kerr
revealed that this family termed Signal Transducers and
Activators of Transcription (STAT) is critical for signaling
new gene expression by the cytokine receptor super-family
[146–148].
The Janus kinases (JAK) were identified by Jim Ihle's
group as important for signaling via erythropoietin (EPO)
receptors [149], and subsequently many of the receptors
for the interleukins and hematopoietic colony stimulating
activities that are members of the same super-family of cy-
tokines and receptors were found to activate distinct
members of the JAK family [150]. These experiments thus
showed how the JAKs connect the cytokine receptors with
the STATs. As pointed out by O'Shea, future research into
agents that either inhibit or enhance the activities of these
molecules are obvious areas for drug development to
identify new compounds useful as immunomodulators
[151].
Antigen processing and presentation
Despite all of these advances, particularly in understand-
ing that the TCR belongs to the same family as do anti-
body molecules, and that the hormones of the immune
system regulate lymphocyte proliferation and differentia-
tion, the requirement for MHC restriction of antigen rec-
ognition by T cells remained an enigma. However, there
were several discoveries that gradually clarified the molec-
ular mechanisms responsible for these phenomena. First,
in the 1960s, Stuart Schlossman and coworkers had
shown that very short peptides with as few as 6 amino ac-
ids, could be recognized during cell mediated immunity
[152]. Also, as early as 1968, Unanue and Askonas [153]
showed that despite rapid degradation of radiolabled an-
tigen by macrophages, these cells remained immunogenic
for as long as 3 weeks. Then, in 1982 Zeigler and Unanue
[154] showed that the catabolism of antigen by macro-
phages was actually necessary for their capacity to present
antigen to T cells.
Moreover, already in 1969, George Mackaness had shown
that antigen-activated lymphocytes activate macrophages
to kill intracellular microbes [155]. Soon thereafter, this
macrophage activation was found to be due to a soluble
lymphocyte-derived factor by John David's lab [156,157].
Then, Michael Tovey working with Ion Gresser's group
showed that interferons, which had such potent antiviral
activity, also promoted the expression of histocompatibil-
ity antigens [158,159]. In 1983 this macrophage activat-
ing factor (MAF) activity was shown to be interferon-
(IFN-) by Henry Murray, Carl Nathan and Bob Schreiber
their co-workers [79,160,161]. Now it is known that IFN-
 upregulates just about everything that macrophages are
capable of doing, including antigen processing and pres-
entation, in addition to phagocytosis and intracellular
killing.
In 1985, Unanue's group demonstrated that "processed"
protein antigens of short peptides (10 amino acids) actu-
ally bind to MHC molecules inside the cell, prior to ap-
pearing on the cell surface [162]. Subsequently, in 1987
Pam Bjorkman, working as a doctoral student with Don
Wiley and Jack Strominger, solved the 3 dimensional crys-
tal structure of the first MHC encoded molecule [163].
The visualization of the structure of a MHC molecule was
a revelation: Two parallel alpha helices form a pocket
where short antigenic peptides reside. Thus, T cells recog-
nize peptide antigens bound to MHC-encoded molecules,
and antigen presenting cells (APCs) process complex pro-
teins by degradation to short peptides of 8–15 amino ac-
ids. This information, combined with structural
information from Ig molecules and the knowledge that
the TCR chains are homologous to Ig molecules provided
a picture for the first time of the way in which the TCR
docks onto the peptide-MHC molecular complex [164].
Lymphocyte development
With the generation of monoclonal antibodies recogniz-
ing distinct CDs, Reinherz and coworkers introduced the
notion of using these markers to track the maturation of
lymphocytes [165]. Scollay and Shortman then led thePage 7 of 17
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distinguished by their differential expression of surface
markers detected by flow cytometry [166,167]. However,
the cause and effect of changes in surface marker expres-
sion vs. functional maturation of the TCR and accessory
molecules was more difficult to assess. Ada Kruisbeek and
coworkers reported seminal experiments, showing that
monoclonal antibodies reactive with MHC Class II mole-
cules administered to neonatal mice prevented the devel-
opment of CD4+ T cells, thereby providing proof of the
concept that signals passing from the thymic stromal
MHC molecules to thymic TCRs was important for T cell
maturation [168,169]. Subsequently, using mice express-
ing transgenic TCRs, von Boehmer's group showed une-
quivocally that the interaction of the TCR on the
immature thymocyte with MHC molecules on thymic
supporting cells determines the positive selection of thy-
mocytes into "single-positive", CD4+ or CD8+ T cells rec-
ognizing non-self epitopes, and negative selection of self-
reactive TCRs [170–172].
In the 25 years since the realization that antibody diversity
is generated by the rearragement and recombination of
immunoglobulin genes, a multitude of investigators have
studied the processes by which these phenomena occur.
Early B and T cell precursors generate antigen recognition
diversity by assembling the exons that encode Ig or TCR
variable regions from individual variable (V), diversity
(D), and joining (J) gene segments through recombina-
tion-activating gene-1 (RAG-1) and RAG-2 proteins as
shown by Baltimore's group [173].
Much of the work on lymphocyte development was per-
formed initially without consideration of a role played by
cytokines. However, with Namen's discovery of IL7
[74,174], first as a growth and differentiation factor direct-
ed toward immature B cells, then as a cytokine that also
promotes the proliferation and survival of immature thy-
mocytes, many of the developmental changes found to
take place are now known to actually be mediated by IL7.
Most of the severe combined immunodeficiencies (i.e.
70–80%) have been traced to mutations that affect the IL7
pathway. Consequently, within the past several years,
Crystal Mackall and her group have reported on the effects
of the administration of IL7 to both normal and T cell de-
pleted mice [175,176]. The data indicate that IL7 may well
be an effective cytokine to accelerate the recovery of the
immune system after bone marrow transplantation or ac-
quired immunodeficiency [177].
Dendritic cell lines
In 1992 Blanchereau's group working with human cells
[178] and independently, Gerold Schuler, working with
murine cells along with Kayo Inaba and Ralph Steinman
[179], reported that GM-CSF promotes the proliferative
expansion of mononuclear cells with the characteristics of
dendritic cells (DCs). DCs had remained a curiosity for al-
most 20 years, because they are present in such low num-
bers in lymphoid cell populations, usually < 1%.
Consequently, obtaining enough cells for molecular stud-
ies was difficult. By comparison, tissue macrophages and
DCs are very prevalent, but difficult to access. However,
the discovery that GM-CSF acts as a myeloid lineage-spe-
cific growth and differentiation factor like EPO is for
erythroid cells, and the subsequent finding by Schuler and
his coworkers that the addition of IL4 prevents differenti-
ation to macrophages thereby facilitating the GM-CSF-
driven default pathway of differentiation to DCs, fueled
an explosion of work in this area [180].
Originally, it was thought that DCs were a separate cell
lineage that differentiated from a common myeloid stem
cell precursor, present in very small numbers in bone mar-
row and blood [179]. However, from studies by Lanzavec-
chia's group, it is now evident that blood monocytes
differentiate into "immature DCs" when acted upon by
GM-CSF and IL4 [181,182]. In the absence of IL4, GM-
CSF promotes the differentiation of monocytes to macro-
phages. Thus, DCs are not a separate myeloid cell lineage,
but rather a differentiation pathway of myeloid cells,
much like the differentiation of Th-1 and Th-2 cells, which
is also under the supervision of cytokines such as IL4 and
IFN-.
Moreover, the switch from immature DCs which are effi-
cient at antigen capture, to "mature DCs", which acquire
attributes that facilitate antigen presentation, is signaled
by a variety of stimuli that are associated with severe infec-
tion, including whole bacteria [183], bacterial endotoxin
[182], bacterial DNA [184], and especially pro-inflamma-
tory cytokines such as IL1 and TNF-, while IL10 inhibits
this differentiative process [185]. Of particular impor-
tance, mature DCs secrete large amounts of IL12, and ex-
press high levels of MHC Class II molecules, as well as
CD40, co-stimulatory and adhesion molecules, all of
which make for very efficient antigen presentation and ac-
tivation of T cells. As well, it is important to emphasize
that many of the ligands that impact mature DCs signal
the activation of NF-B transcription factors, of which c-
Rel is the most important.
Recently, Fred Siegal's group reported a new type of DC,
termed a plasmacytoid DC (pDC) that is thought to derive
from a lymphoid lineage, in that it expresses CD4 and
CD123, but not CD11c, a marker for the myeloid lineage
[186]. pDCs are also distinguished from their myeloid
cousins by their marked production of IFN- upon induc-
tion with viruses and bacteria. By selecting for pDCs, the
production of IFN- is enhanced ~600-fold, while mono-
cytes-derived DCs produce barely detectable amounts. AsPage 8 of 17
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presence of IL3 and CD40L, while myeloid DCs require
GM-CSF and IL4. Given the growing awareness of the phe-
notypic and functional diversity of DCs, the derivation of
distinct DC clones seems warranted.
In retrospect, given the role of DCs in the activation of
lymphocytes and their production of pro-inflammatory
cytokines such as TNF-, the toxicity of Coley's toxins
(heat-killed bacterial extracts) can now be better under-
stood. In addition, given the role of adjuvants that contain
bacterial extracts, such as Complete Freund's Adjuvant
(CFA), in promoting maximal activation of the immune
system by vaccines, investigators are now exploring DCs
as a new adjuvant form of cellular therapy [187]. Thus far,
DCs have been employed in cancer therapy studies, with
some promising initial results, but many issues remain to
be explored, including optimal cell numbers, ease of prep-
aration, frequency of administration, and potential side
effects [188].
B cell clones and B cell Differentiation
With much of the immunologic community focused on T
cells, B cells received comparatively much less attention in
the '80s. However, in 1991, Jacques Banchereau's group
reported that it is possible to promote the long-term
growth and clonal isolation of normal human B cells by
stimulating them with a combination of IL4 and mono-
clonal antibodies reactive with CD40, a member of the
TNFR family [189,190]. Thus, large numbers of normal B
cells could finally be obtained in a manner analogous to
the long-term growth of T cells and NK cells. Soon there-
after, Seth Lederman working in Len Chess's group, re-
ported the derivation of a monoclonal antibody reactive
with a T helper cell surface activation molecule, which is
now known as CD40 ligand (CD40-L) [191,192]. Thus, T
cell "help" for B cells was shown to be mediated by both
a soluble cytokine provided by the Th cells (IL4), and by
a T cell surface ligand (CD40-L). Almost immediately,
Raif Geha's group showed that the genetic defect of the
"Hyper-IgM syndrome", where there is a defect in B cell Ig
isotype switching, is ascribable to mutations in T cell ex-
pression of CD40-L [193].
After mature B cells leave the bone marrow and populate
the peripheral lymphoid tissues, they further diversify the
antibody repertoire through two antigen-dependent proc-
esses that usually occur in the germinal center of second-
ary lymphoid organs. These are Ig V(D)J gene somatic
mutation, which increases the antibody affinity for anti-
gen by introducing point mutations within the V(D)J
exon [194], and Ig heavy chain class switching, which
modifies the antibody effector functions by substituting
the constant region of IgM with that of IgG, IgA, or IgE
[195]. Hypermutated and class-switched germinal center
B cells give rise to long-lived memory B cells or terminally
differentiate to plasma cells, which secrete large amounts
of immunoglobulin.
Experiments using cloned human lymphoma cells by Pao-
lo Casalli and his group have revealed that somatic hyper-
mutation is signaled by activation of the BCR, but that
help is required from T cells via engagement of the
CD40L-CD40 and CD28-CD80 ligand receptor systems
[196]. By comparison, this same group found that class
switch recombination (CSR) is dependent upon the
CD40L-CD40 triggering by Th cells, but as well, cytokines
such as IL10, IL4, and TGF- are required [197]. Now An-
drea Cerutti with Casalli and their coworkers have found
that IFN-, IFN- or CD40L upregulate the TNF family
members BlyS and APRIL on DCs. Then in the presence of
IL10 or TGF-, BlyS and APRIL on DCs induce CSR from
C to C and/or C genes in B cells, whereas CSR to C
requires IL4 [198]. Secretion of class switched antibodies
requires additional stimulation by BCR engagement and
IL15. Thus, unlike T cell-dependent class switching, T cell-
independent class switching, which occurs in splenic mar-
ginal zone or intestinal lamina propria B cells, provides
prompt protection against invading pathogens. Similar
findings have also been reported by John Kearney and his
group [199]. The implications for these new findings for
host defenses, especially against encapsulated bacteria, are
obvious.
Innate immunity: toll-like receptors (TLR)
In a separate, but related area of research, recent detailed
genetic studies finally solved the mystery underlying the
C3H-HeJ mouse, which is resistant to shock induced by
bacterial endotoxin or lipopolysccharide (LPS) [200]. The
story originated in 1976 with the first description of a sol-
uble factor induced by the injection of LPS that induced
the necrosis of tumors by Lloyd Old's group [201]. Subse-
quently, Tony Cerami's group reported that LPS induced
the inhibition of lipoprotein lipase activity by a factor that
they termed cachectin, which led to a paradoxical hyperli-
pemia in a situation of a chronic wasting syndrome [202].
Subsequently, the cDNA for tumor necrosis factor-alpha
(TNF-) was cloned and sequenced by David Goedell's
group [203]. Soon thereafter, Beutler purified, cloned and
sequenced cachectin [204], and it was realized that TNF-
and cachectin are one in the same [87]. More than a dec-
ade later, after painstaking chromosome walking experi-
ments Bruce Beutler's group solved the mysterious lack of
the ability of C3H-HEJ mice to respond to LPS only in
1998 [200]. The genetic defect resides in a receptor origi-
nally discovered in fruit flies, the Toll receptor family.
Thus, the LPS receptor is now known to be the Toll-Like
Receptor-4 (TLR-4). This receptor is expressed at high lev-
els on APCs, especially mature DCs. Moreover, TLRs acti-Page 9 of 17
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particularly c-Rel.
This discovery has led to a virtual cornucopia of research.
For example, Herman Wagner and his collaborators have
shown that there are TLRs for bacterial DNA, which has a
preponderance of CpG sequences (TLR-9) [205], and Fla-
vell's group has found that double-stranded RNA, long
known to induce interferon and augment immune re-
sponses, binds to TLR-3 [206]. These receptors recognize
repeating molecules, and they are now known as pattern
recognition receptors. Doubtless, activation of TLRs will
be a fruitful future area of research for those interested in
both augmenting and suppressing immune responses.
Structure-activity relationships of the peptide-
MHC-TCR complex
During this same interval, the structure-activity-relation-
ships between the TCR on CD8+ T cells interacting with
antigenic peptides bound to Class I MHC-encoded mole-
cules and CD4+ T cells interacting with antigenic peptides
bound to Class II MHC-encoded molecules were elucidat-
ed for the first time by groups led by Don Wiley, Ian Wil-
son and Ellis Reinherz [207–209]. Analysis of the
intermolecular interaction at the atomic level is revealing
subtleties that promise to explain such fundamental im-
munological issues as positive and negative selection dur-
ing T cell maturation in the thymus, the capacity of CD4+
T cell TCRs to recognize multiple peptide-MHC (p-MHC)
ligands, and how alloreactivity differs from the recogni-
tion of foreign peptides bound to self MHC [210].
In addition, John Altman, working in Mark Davis' group
capitalized on the new understanding of how p-MHC
complexes bind to the TCR to develop a new way to iden-
tify antigen-specific T cells [211]. By forming tetramers of
MHC molecules, which can then be loaded with antigenic
peptides, it is possible to improve the affinity of p-MHC-
TCR binding so that the tetramer-bound cells can be de-
tected by flow cytometry. This assay can then be used to
enumerate the frequency of antigen-reactive T cells before,
during and after an immune reaction. As well, Florian
Kern and coworkers improved the detection of antigen ac-
tivated T cells by using mixtures of overlapping peptides
to stimulate cytokine production by both CD4+ and
CD8+ T cells, which can then be detected by using ELIS-
POT and flow cytometry [212–214]. Accordingly, just as
in the determination of the amount of antibody produced
after antigenic exposure, it is now possible for the first
time to quantify the T cell immune response.
Recent experiments by Mark Davis, Michael Dustin, Paul
Allen, and their co-workers focused on the question of the
threshold of TCR activation by p-MHC complexes has re-
vealed that a TCR "synapse" forms, creating a specialized
junction between a T cell and an antigen-presenting cell
[215]. Immunological synapse formation is a dynamic
mechanism that allows T cells to distinguish activating lig-
ands from those that are not of sufficient "strength" to re-
sult in immunological recognition. Fully formed, the T
cell synapse consists of a central cluster of TCR-p-MHC
molecules surrounded by a ring of adhesion molecules.
However, prior to engagement, TCR-p-MHC complexes
form an outer ring of the nascent synapse. Transport of
these complexes into the center of a cluster, so that the ad-
hesion molecules form an outermost stabilizing ring is de-
pendent upon TCR-p-MHC reaction kinetics and is at the
essence of determining "immune recognition".
Fc receptors (FcR): connecting humoral and cel-
lular immunity
From the humoral side of immunity, it was thought since
the days of Metchnikov, Arthus, Shick and von Pirquet
that the inflammatory responses observed during allergic
and autoimmune reactions were due to antigen-antibody
(Ag-Ab) complexes, which activated polymorphonuclear
leukocytes (PMNs, the microphages of Metchnikov) via
complement (C') ("Arthus Reaction"). In a seminal series
of reports by Jeff Ravetch and his group, the pathogenesis
of these inflammatory phenomena are now known to be
due to the activation of macrophages and mast cells via
antigen-IgG complexes binding to and triggering Fc recep-
tors (FcR), which then results in their production of proin-
flammatory cytokines [216–218]. Therefore, there is a
synergism between the humoral and cellular arms of the
immune response that mediates the end result, which is
the release of inflammatory cytokines. By comparison,
their work has shown that C' works together with "natu-
ral" IgM antibodies to lyse bacteria and other cellular tar-
gets without the participation of FcR on macrophages or
PMNs [219].
In addition, both IgG and IgE FcRs participate in the acti-
vation of mast cells, leading to their degranulation and re-
lease of the vasoactive amines that produce the immediate
hypersensitivity reaction so characteristic of allergic reac-
tions [220]. Finally, as a result of Ravetch's work, there are
now known to be inhibitory FcRs that bind Ag-IgG com-
plexes that serve to attenuate humoral immunity [221], so
that manipulations that activate either the stimulatory
and inhibitory FcRs are prime targets for the discovery of
new immunomodulatory agents.
Because the common pathway of all of these phenomena
initiated by the formation of Ag-Ab complexes is mediat-
ed via pro-inflammatory cytokines, it is not too much of a
stretch to imagine that monoclonal antibodies reactive
with TNF- or soluble TNFRs may be effective in the treat-
ment of such diseases as polyarteritis nodosa, even before
we understand the underlying pathogenesis, just as theyPage 10 of 17
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conditions. As well, drugs such as Cyclosporine A and
FK506 that block signaling via the FcRs should be effective
in the treatment of allergic and other inflammatory dis-
eases.
The genomic age
Having identified the cells responsible for mediating the
host defenses, the cytokines that direct their maturation,
proliferation, differentiation and survival, the cell surface
receptors responsible for transferring extracellular signals
to the cell interior, and the signaling molecules/transcrip-
tion factors that serve as second messengers emanating
from the receptors, the identification of the genes that en-
code the molecules activated now represents a new area of
research that promises to have major impact on the evolu-
tion of medical immunology.
Following the lead of Chuck Stiles who 20 years ago first
cloned genes expressed by fibroblasts stimulated with
Platelet-Derived Growth Factor [222], Carol Beadling ini-
tiated experiments a decade ago in our lab to identify and
clone IL2-induced genes [223]. At the same time, Jacques
Theze's group have also pioneered this approach [224].
Now, it is evident that DNA arrays will provide the neces-
sary technology to identify the genes responsible for all of
the complex processes that we recognize as the immune
response. Thus, we should anticipate the discovery of
many new genes and gene products that can serve as tar-
gets for future therapeutic intervention into the immune
system.
Advances in molecular genetics have already made it pos-
sible to express or delete specific genes in mice so that re-
ductionism can now be combined with reconstructionist
science to provide insight into disease mechanisms. For
example, Stefan Ehler's group has performed a tour de
force in experiments directed at understanding the mech-
anisms responsible for "Koch's phenomenon". Using
mice with deletions of individual genes thought to be in-
volved, they demonstrated unequivocally that T cells and
IFN- are obligatory for the caseous necrosis of tubercu-
loid granuloma, long an unexplained aspect of a classic
cell-mediated immune reaction involving the interaction
between T cells and macrophages in TB [225]. These ex-
periments show the way to the determination of the cells
and molecules that play a role in other immunological
disease processes, so that rational interventions can be de-
vised.
A century after Pasteur proposed that it might be possible
to attenuate microbes, which could then be used as vac-
cines, because of genetic engineering, it is now possible to
remove "virulence genes" from microbes and replace
them with genes that can be expressed in their place,
thereby immunizing with "safe" microbes. For example,
one of the viruses that is being developed as a vaccine for
the Human Immunodeficiency Virus (HIV) is a modified
version of Jenner's cowpox virus, vaccinia [226]. Another,
similar virus being developed is the canarypox virus [226].
Since the poxviruses are large, with > 200 genes, they
make it possible to remove and replace genes without
markedly altering the infectivity of the virus or the capac-
ity of the altered virus to express the newly inserted genes
[227–229]. Accordingly, Pasteur's dream of vaccines
against the entire microbial world may finally become a
reality.
An additional area where the genomic revolution promis-
es to have a major impact is on the identification of anti-
genic epitopes, especially for T cells. As the genomic
sequences of all of the various microbes become com-
plete, it will be possible to use the sequence information
to analyze potential peptide sequences for possible bind-
ing to the various MHC molecules, as well as whether
there are side chains capable of impacting TCRs. Thus, the
idea of "molecular mimicry" as a cause of autoimmunity
will finally become testable. As well, many allergies due to
cross-reactive epitopes of distinct allergens will finally be-
come illuminated.
Conclusions
From this historical perspective, one can now see how the
vision of our forefathers was not misplaced. Now, it is
possible to generate and use antibodies as therapy, and it
is possible to attenuate microbes to construct vaccines for
the prevention of infectious diseases. However, in addi-
tion to these approaches envisioned 100 years ago, now
that we have applied a reductionist approach to such a
complex biological system over the past 30 years, we have
identified the cells that comprise the immune system, and
we have isolated individual clones of all of the major cell
types that participate. As well, we have reconstituted the
immune response in vitro and we have been able to deter-
mine how the cells recognize foreign molecules, and how
they communicate with one another through cell surface
ligand/receptor systems and through secreted hormones.
Moreover, we have discerned how the system responds to
the introduction of foreign material, first by massively ex-
panding the number of cells reactive to the invading mol-
ecules, and then by their differentiation into cells that
produce an amazing array of immunologic effector mole-
cules. Consequently, we now have available to us a much
more enlightened understanding of the physiology of the
immune system, and as well, multiple cells and molecules
to craft new approaches to the diagnosis, therapy and pre-
vention of diseases that impact the immune system. It is
now timely for a renaissance of Medical Immunology.
Our new journal is meant to provide for a forum and a
medium to voice this new subspecialty of medicine thatPage 11 of 17
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nicians alike.
References
1. Bernard C:  An Introduction to the Study of Experimental Medicine. New
York: Dover Publishers Inc. 1865
2. Jenner E:  An Inquiry into the Causes and Effects of Variolae Vaccinae, a
Disease Discovered in Some Western Counties of England. London: Samp-
son Low 1798
3. Koch R: Die aetiologie der milzbrand-krankheit, begrundet
auf die entwicklungsgeschichte des bacillus antracis. Beitrage
zur Biologie der Pflanzen 1877, 2:277-310
4. Pasteur L, Joubert , Chamberland : La theorie des germes et ses
applications a la medicine et a la chirurgie. Comptes Rendus
Hebdomadaires des Seances de l'Academie des Sciences 1878, 86:1037-
1043
5. Pasteur L: Sur les maladies virulentes, et en particulier sur la
maladie appelee vulgairement cholera des poules. Comptes
Rendus Hebdomadaires des Seances de l'Academie des Sciences 1880,
90:249-248
6. Pasteur L, Chamberland , Roux : De l'attenuation des virus et de
leur retore a la virulence. Comptes Rendus des Seances de L'Acade-
mie des Sciences 1881, 92:430-435
7. Metchnikoff E:  Immunity in Infective Diseases. Cambridge, UK: Cambridge
University Press 1905
8. Behring EAS, Kitasato K: Ueber das zustandekommen der diph-
therie-immunaitat und der tetanus-immunitat bei thieren.
Deutsche Medizinische Wochenschrift 1890, 16:113-114
9. Portier P, Richet C: De l'action anaphylactique de certains
venins. Comptes Rundus des Seances de la Societe de Biologie et des Fil-
ials 1902, 54:170-172
10. Arthus M: Injections repitees de serum de cheval chez le lapin.
Comtes Rendus des Seances de la Societie de Biologie et de ses Filiales
1903, 817-820
11. von Pirquet C, Shick B:  Serum Sickness. Baltimore: The Williams and
Wilkins Co. 1951
12. Coley W: The treatment of malignant tumors by repeated in-
oculations of erysipalas: with a report of ten original cases.
Am J Med Sci 1893, 10:487-511
13. Landsteiner K, van der Scher J: On cross reactions of immune
sera to azoproteins. J Exp Med 1936, 63:325-339
14. Nowell PC: Phytohemagglutinin: An initiator of mitosis in cul-
tures of normal human leukocytes. Cancer Research 1960,
20:462-468
15. Fagraeus A: The plasma cellular reaction and its relation to
the formation of antibodies in vitro. J Exp Med 1948, 1-13
16. Jerne NK, Nordin AA: Antibody formation in agar by single an-
tibody-producing cells. Science 1963, 140:405
17. Burnet FM: A modification of Jerne's theory of antibody pro-
duction using the concept of clonal selection. Aust J Sci 1955,
20:67-77
18. Raff M, Sternberg M, Taylor RB: Immunoglobulin determinants
on the surface of mouse lymphoid cells. Nature 1970, 225:553-
555
19. Pernis B, Forni L, Amante L: Immunoglobulin spots on the sur-
face of rabbit lymphocytes. J Exp Med 1970, 132:1001-1018
20. Raff M: Surface antigenic markers for distinguishing T and B
lymphocytes. Transplant Rev 1971, 6:52-59
21. Lamelin J, Lisowska-Berntstein B, Matter A, Ryser J, Vassalli P: Mouse
thymus-independent and thymus-derived lymphoid cells. I.
Immunofluorescent and functional studies. J Exp Med 1972,
136:984-1007
22. Steinman R, Cohn Z: Identification of a novel cell type in pe-
ripheral lymphoid organs of mice. J Exp Med 1973, 137:1142-
1162
23. Herberman RB, Nunn ME, Holden HT, Lavrin DH: Natural cyto-
toxic reactivity of mouse lymphoid cells against syngeneic
and allogeneic tumors. II. Characterization of effector cells.
Int J Cancer 1975, 16:230-239
24. Kiessling R, Klein E, Wigzell H: Natural killer cells in the mouse.
I. Cytotoxic cells with specificity for mouse Moloney leuke-
mia cells. Specificity and distribution according to genotype.
Eur J Immunol 1975, 5:112-116
25. Benacerraf B, Gell P: Studies on hypersensitivity. I. Delayed and
Arthus-type skin reactivity to protein conjugates in guinea
pigs. Immunol 1959, 2:53-63
26. Gell P, Benacerraf B: Studies on hypersensitivity. II. Delayed hy-
persensitivity to denatured proteins in guinea pigs. Immunol
1959, 2:64-70
27. Kantor FS, Ojeda A, Benacerraf B: Studies on artificial antigens I.
Antigenicity of DNP-polylysine and DNP copolymer of lysine
and glutamic acid in guinea pigs. J Exp Med 1963, 117:55-64
28. Green I, Paul WE, Benacerraf B: The behavior of hapten-poly-L-
lysine conjugates as complete antigens in genetic responder
and as haptens in non-responder guinea pigs. J Exp Med 1966,
123:859-879
29. McDevitt HO, Tyan ML: Genetic control of the antibody re-
sponse in inbred mice: Transfer of response by spleen cells
and linkage to the major histocompatability (H2) locus. J Exp
Med 1968, 128:1-11
30. McDevitt HO, Chinitz A: Genetic control of the antibody re-
sponse: Relationship between immune response and histo-
compatability (H-2) type. Science 1969, 163:273-279
31. Katz D, Hamaoka T, Benacerraf B: Cell interactions between his-
toincompatible T and B lymphocytes II. Failure of physiolog-
ic cooperative interactions between T and B lymphocytes
from allogeneic donor strains in humoral response to hap-
ten-protein conjugates. J Exp Med 1973, 137:1405-1418
32. Rosenthal A, Shevach E: Function of macrophages in antigen
recognition by guinea pig T lymphocytes. I. Requirement for
histocompatible macrophages and lymphocytes. J Exp Med
1973, 138:1194-1212
33. Zinkernagel R, Doherty P: Restriction of in vitro T cell-mediated
cytotoxicity in lymphocytic choriomeningitis within a syn-
geneic or semiallogeneic system. Nature 1974, 248:701-702
34. Kohler G, Milstein C: Continuous culture of fused cells secret-
ing antibody of predefined specificity. Nature 1975, 256:495-499
35. Hozumi N, Tonegawa S: Evidence for somatic rearrangement
of immunoglobulin genes coding for variable and constant
regions. Proc Natl Acad Sci U S A 1976, 73:3628-3632
36. Tonegawa S, Brack C, Hozumi N, Schuller R: Cloning of an immu-
noglobulin variable region gene from mouse embryo. Proc
Natl Acad Sci U S A 1977, 74:3518-3523
37. Bernard O, Hozumi N, Tonegawa S: Sequences of mouse immu-
noglobulin light cain genes before and after somatic changes.
Cell 1978, 15:1133-1139
38. Seidman J, Edgell M, Leder P: Immunoglobulin light chain struc-
tural gene sequences cloned in a bacterial plasmid. Nature
1978, 271:582-586
39. Jakobovits A, Moore AL, Green LL, Vergara GJ, Maynard-Currie CE,
Austin HA, Klapholz S: Germ-line transmission of a human-de-
rived yeast artificial chromosome. Nature 1993, 362:255-258
40. Green LL, hardy MC, Maynard-Currie CE, Tsuda H, Louie DM, Men-
dez MJ, Abderrahim H, Noguchi M, Smith DH, Zeng NE, David NE,
Sasai H, Garza D, Brenner DG, Hales JF, McGuinness RP, Capon DJ,
Klapholz S, Jakobovits A: Antigen-specific human monoclonal
antibodies from mice engineered with human Ig heavy and
light chain YACS. Nature Genetics 1994, 7:13-21
41. Lanier L, Engleman E, Gatenby P, Babcock G, Warner N, Herzenberg
L: Correlation of functional properties of human lymphoid
cell subsets and surface marker phenotypes using multipa-
rameter analysis and flow cytometry. Immunol Rev 1983,
74:143-160
42. Schlossman S: Characterization and function of human lym-
phocyte subsets. Prog Clin Biol Res 1981, 58:3-6
43. Nadler L, Ritz J, Griffin J, Todd R, Reinherz E, Schlossman S: Diagno-
sis and treatment of human leukemias and lymphomas uti-
lizing monoclonal antibodies. Prog Hematol 1981, 12:187-225
44. Reinherz EL, Hussey RE, Schlossman SF: A monoclonal antibody
blocking human T cell function. Eur J Immunol 1980, 10:758-762
45. Reinherz EL, Kung PC, Goldstein G, Schlossman SF: Separation of
functional subsets of human T cells by a monoclonal anti-
body. Proc Natl Acad Sci USA 1979, 76:4061-4065
46. Kung P, Goldstein G, Reinherz EL, Schlossman SF: Monoclonal an-
tibodies defining distinctive human T cell surface antigens.
Science 1979, 206:347-349
47. Ritz J, Schmidt R, Michon J, Hercend T, Schlossman S: Characteri-
zation of functional surface structures on human natural kill-
er cells. Adv Immunol 1988, 42:181-211Page 12 of 17
(page number not for citation purposes)
Medical Immunology  2002, 1 http://www.medimmunol.com/content/1/1/148. Breard J, Reinherz E, Kung P, Goldstein G, Schlossman S: A mono-
clonal antibody reactive with human peripheral blood mono-
cytes. J Immunol 1980, 124:1943-1948
49. Baker PE, Gillis S, Smith KA: Monoclonal cytolytic T-cell lines. J
Exp Med 1979, 149:273-278
50. Morgan DA, Ruscetti FW, Gallo R: Selective in vitro growth of T
lymphocytes from normal human bone marrows. Science
1976, 193:1007-1008
51. Gillis S, Smith KA: Long term culture of tumour-specific cyto-
toxic T cells [letter]. Nature 1977, 268:154-156
52. Gillis S, Baker PE, Ruscetti FW, Smith KA: Long-term culture of
human antigen-specific cytotoxic T cell lines. Journal of Experi-
mental Medicine 1978, 148:1093-1098
53. Sredni B, Schwartz R: Antigen-specific, proliferating T lym-
phocyte clones. Methodology, specificity, MHC restriction
and alloreactivity. Immunol Rev 1981, 54:187-223
54. Allison J, McIntyre B, Bloch D: Tumor-specific antigen of murine
T-lymphoma defined with monoclonal antibody. J Immunol
1982, 129:2293-2300
55. Meuer SC, Fitzgerald KA, Hussey RE, Hodgdon JC, Schlossman S, Re-
inherz EL: Clonotypic structures involved in antigen-specific
human T cell function. Relationship to the T3 molecular
comlex. J Exp Med 1983, 157:705-719
56. Meuer SC, Hodgdon JC, Hussey RE, Protentis JP, Schlossman S, Rein-
herz EL: Antigen-like effects of monoclonal antibodies direct-
ed at receptors on human T cell clones. J Exp Med 1983,
158:988-993
57. Haskins K, Kubo R, Pigeon M, White J, Kappler J, Marrack P: The ma-
jor histocompatability compex restricted antigen receptor
in T cells. I. Isolation with a monoclonal antibody. J Exp Med
1983, 157:1149-1158
58. Acuto O, Hussey R, Fitzgerald K, Protentis J, Meuer S, Schlossman S,
Reinherz E: The human T cell receptor: Appearance in on-
togoney and biochemical relationship of alpha and beta sub-
units on IL2-dependent clones and T cell tumors. Cell 1983,
34:717-726
59. McIntyre B, Allison J: The mouse T cell receptor: Structural
heterogeneity of molecules of normal T cells defined by
xenoantiserum. Cell 1983, 34:739-746
60. Kappler J, Kubo R, Haskins K, White J, Marrack P: The mouse T cell
receptor: Comparison of MHC-restricted recptors on two T
cell hybridomas. Cell 1983, 34:727-737
61. Hedrick S, Cohen D, Nielson E, Davis MM: Isolation of cDNA
clones encoding T cell-specific membrane associated pro-
teins. Nature 1984, 308:149-155
62. Dennert G: Cloned lines of natural killer cells. Nature 1980,
287:47-49
63. Dennert G, Yogeeswaran G, Yamagata S: Cloned cell lines with
natural killer activity. Specificity, function, and cell surface
markers. J Exp Med 1981, 153:545-556
64. Hercend T, Reinherz E, Meuer S, Schlossman S, Ritz J: Phenotypic
and functional heterogeneity of human cloned natural killer
cell lines. Nature 1983, 301:158-160
65. Hercend T, Griffin J, Bensussan A, Schmidt R, Edson M, Brennan A,
Murray C, Daley J, Schlossman S, Ritz J: Generation of monoclonal
antibodies to a human natural killer clone. Characterization
of two natural killer-associated antigens, NKH1A and NKH2,
expressed on subsets of large granular lymphocytes. J Clin In-
vest 1985, 75:932-943
66. Gillis S, Ferm MM, Ou W, Smith KA: T cell growth factor: param-
eters of production and a quantitative microassay for activi-
ty. J Immunol 1978, 120:2027-2032
67. Smith KA, Lachman LB, Oppenheim JJ, Favata MF: The functional
relationship of the interleukins. J Exp Med 1980, 151:1551-1556
68. Gery I, Waksman BH: Potentiation of the T-lymphocyte re-
sponse to mitogens: The cellular source of potentiating me-
diators. J Exp Med 1972, 136:143-155
69. Isakson P, Pure E, Vitteta E, Krammer P: T cell-derived B cell dif-
ferentiation factor(s): effeect on the isotype switch of
murine B cells. J Exp Med 1982, 155:734-748
70. Howard M, Farrar J, Hilfiker M, Johnson B, Takatsu K, Hamaoka T,
Paul WE: Identification of a T cell-derived B cell growth factor
distinct from interleukin 2. J Exp Med 1982, 155:914-923
71. Takatsu K, Harada N, Hara Y, Takahama Y, Yamada G, Dobashi K,
Hamaoka T: Purification and physicochemical characteriza-
tion of murine T cell replacing factor (TRF). J Immunol 1985,
134:382-389
72. Hirano T, Taga T, Nakano N, Yasukawa K, Kashiwamura S, Shimizu
K, Nakajima K, Pyun KH, Kishimoto T: Purification to homogene-
ity and characterization of human B-cell differentiation fac-
tor (BCDF or BSFp-2). Proc Natl Acad Sci U S A 1985, 82:5490-
5494
73. Gately MK, Wilson DE, Wong HL: Synergy between recom-
binant interleukin 2 (rIL2) and IL2-depleted lymphokine-
containing supernatants in fcilitating allogeneic human cyto-
lytic T lymphocyte responses in vitro. J Immunol 1986,
136:1274-1282
74. Namen A, Schmierer A, March C, Overell R, Park L, Urdal D, Mochi-
zuki D: B cell precursor growth-promoting activity. Purifica-
tion and characterization of a growth factor active on
lymphocyte precursors. J Exp Med 1988, 167:988-1002
75. Vieira P, de Waal-Malefyt R, Dang M-N, Johnson K, Kastelein R,
Fiorentino D, de Vries J, Roncarolo M-G, Mosmann T, Moore K: Iso-
lation and expression of human cytokine synthesis inhibitory
factor cDNA clones: Homology to Epstein-Barr virus open
reading frame BCRF1. Proc Natl Acad Sci U S A 1991, 88:1172-1176
76. Chan S, Perussia B, Gupta J, Kobayashi M, Pospisil M, Young H, Wolf
S, Young D, Clark S, Trinchieri G: Induction of interferon gamma
production by natural killer cell stimulatory factor: charac-
terization of the responder cells and synergy with other in-
ducers. J Exp Med 1991, 173:869-879
77. Burton J, Bamford R, Peters C, Grant A, Kurys G, Goldman C, Bren-
nan J, Roessler E, Waldmann T: A lymphokine, provisionally des-
ignated interleukin T and produced by a human adult T-cell
leukemia line, stimulates T-cell proliferation and the induc-
tion of lymphokine-activated killer cells. Proc Natl Acad Sci U S A
1994, 91:4935-4939
78. Grabstein K, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V,
Beers C, Richardson J, Schoenborn M, Ahdieh M, et al: Cloning of a
T cell growth factor that interacts with the beta chain of the
interleukin-2 receptor. Science 1994, 264:965-968
79. Schreiber R, Pace J, Russell S, Altman A, Katz D: Macrophage-acti-
vating factor produced by a T cell hybridoma: physiochemi-
cal and biosynthetic resemblance to gamma-interferon. J
Immunol 1983, 131:826-832
80. Burgess A, Camakaris J, Metcalf D: Purification and properties of
colony-stimulating factor from mouse lung-conditioned me-
dium. J Biol Chem 1977, 252:1998-2003
81. Gough N, Gough J, Metcalf D, Kelso A, Grail D, Nicola N, Burgess A,
Dunn A: Molecular cloning of cDNA encoding a murine hae-
matopoietic growth regulator, granulocyte-macrophage col-
ony stimulating factor. Nature 1984, 309:763-767
82. Naito K, Inaba K, Hirayama Y, Inaba-Miyama M, Sudo T, Muramatsu
S: Macrophage factors which enhance the mixed leukocyte
reaction initiated by dendritic cells. J Immunol 1989, 142:1834-
1839
83. Smith KA, Favata MF, Oroszlan S: Production and characteriza-
tion of monoclonal antibodies to human interleukin 2: strat-
egy and tactics. J Immunol 1983, 131:1808-1815
84. Budd R, Smith KA: Interleukin 2 immunoassay using mono-
clonal antibodies. Biotechnology 1986, 4:983-986
85. Openshaw P, Murphy EE, Hosken NA, Maino V, Davis K, Murphy K,
O'Garra A: Heterogeneity of intracellular cytokine synthesis
at the single-cell level in polarized T helper 1 and T helper 2
populations. J Exp Med 1995, 182:1357-1367
86. Green S, Dobrjansky A, Carswell E, Kassel RL, Old LJ, Fiore N, MK S:
Partial purification of a serum factor that causes necrosis of
tumors. Proc Natl Acad Sci USA 1976, 73:381-385
87. Beutler B, Cerami A: Cachectin and tumour necrosis factor as
two sides of the same biological coin. Nature 1986, 320:584-588
88. Tracey K, Beutler B, Lowry S, Merryweather J, Wolpe S, Milsark I,
Hariri R, Fahey T, Zentella A, Albert J, et al: Shock and tissue injury
induced by recombinant human cachectin. Science 1986,
234:470-474
89. Dinarello C, Cannon J, Wolff S, Bernheim H, Beutler B, Cerami A, Fi-
gari I, Palladino M, O'Connor J: Tumor necrosis factor (cachec-
tin) is an endogenous pyrogen and induces production of
interleukin 1. J Exp Med 1986, 163:1433-1450
90. Brennan F, Chantry D, Jackson A, Maini R, Feldman M: Inhibitory ef-
fect of TNF alpha antibodies on synovial cell interleukin-1
production in rheumatoid arthritis. The Lancet 1989, 2:244-247Page 13 of 17
(page number not for citation purposes)
Medical Immunology  2002, 1 http://www.medimmunol.com/content/1/1/191. Williams R, Feldmann M, Maini R: Anti-tumor necrosis factor
ameliorates joint disease in murine collagen-induced arthri-
tis. Proc Natl Acad Sci U S A 1992, 89:9784-9788
92. Elliot M, Maini R, Feldmann M, et al: Repeated therapy with mon-
oclonal antibody to tumor necrosis factor alpha (cA2) in pa-
tients with rheumatoid arthritis. Lancet 1994, 344(1):115-1127
93. Present D, Rutgeerts P, Targan S, et al: Infliximab for the treat-
ment of fistulas in patients with Crohn's disease. N Eng J Med
1999, 340:1398-1405
94. Mosmann T, Cherwinski H, Bond M, Gieden M, Coffman R: Two
types of murine helper T cell clone. I. Definition according to
profiles of lymphokine activities and secreted proteins. J Im-
munol 1986, 136:2348-2357
95. Snapper C, Paul W: Interferon-gamma and B cell stimulatory
factor-I reciprocally regulate Ig isotype production. Science
1987, 236:944-947
96. Cher D, Mosmann T: Two types of murine helper T cell clone.
II. Delayed-type hypresensitivity is mediated by Th-1 clones.
J Immunol 1987, 138:3688-3694
97. Swain S, Weinberg A, English M, Huston G: IL-4 directs the devel-
opment of Th2-like helper effectors. J Immunol 1990, 145:3796-
3806
98. Croft M, Duncan DD, Swain SL: Response of naive antigen-spe-
cific CD4+ T cells in vitro: characteristics and antigen-pre-
senting cell requirements. J Exp Med 1992, 176:1431-1437
99. Le Gros G, Ben-Sasson SZ, Seder R, Finkelman FD, Paul WE: Gener-
ation of interleukin 4 (IL4)-producing cells in vivo and in vit-
ro: IL2 and IL4 are required for in vitro generation of IL4-
producing cells. The J Exp Med 1990, 172:921-929
100. Macatonia S, Hsieh C, Murphy K, O'Garra A: Dendritic cells and
macrophages are required for Th1 development of CD4+ T
cells from alpha beta TCR transgenic mice: IL-12 substitu-
tion for macrophages to stimulate IFN-gamma production is
IFN-gamma-dependent. Int Immunol 1993, 5:1119-1128
101. Macatonia S, Hosken N, Litton M, Vieira P, Hsieh C, Culpepper J,
Wysocka M, Trinchieri G, Murphy K, O'Garra A: Dendritic cells
produce IL-12 and direct the development of Th1 cells from
naive CD4+ T cells. J Immunol 1995, 154:5071-5079
102. Bucy R, Panoskaltsis-Mortari A, Huang G, Li J, Karr L, Ross M, Russell
J, Murphy K, Weaver C: Heterogeneity of single cell cytokine
gene expression in clonal T cell populations. J Exp Med 1994,
180:1251-1262
103. Szabo S, Kim S, Costa G, Zhang X, Fathman C, Glimcher L: A novel
transcription factor, T-bet, directs Th1 lineage commit-
ment. Cell 2000, 100:655-669
104. Solymar D, Agarwal S, Bassing C, Alt F, Rao A: A 3' enhancer in the
IL-4 gene regulates cytokine production by Th2 cells and
mast cells. Immunity 2002, 17:41-50
105. Glimcher L, Murphy K: Lineage commitment in the immune
system: the T helper lymphocyte grows up. Genes Dev 2000,
14:1693-1711
106. Podack ER, Koningsberg PJ: Cytolytic T cell granules. Isolation,
structural, biochemical, and functional characterization. J
Exp Med 1984, 160:695-710
107. Podack ER, Young JD, Cohn ZA: Isolation and biochemical and
functional characterization of peforin 1 from cytolytic T cell
granules. Proc Natl Acad Sci USA 1985, 82:8629-8633
108. Walter E, Greenberg P, Gilbert M, Finch R, Watanabe K, Thomas E,
Riddell S: Reconstitution of cellular immunity against cytome-
galovirus in recipients of allogeneic bone marrow by transfer
of T-cell clones from the donor. N Engl J Med 1995, 333:1038-
1044
109. O'Reilly R, Small T, Papadopoulos E, Lucas K, Lacerda J, Koulova L:
Biology and adoptive cell therapy of Epstein-Barr virus-asso-
ciated lymphoproliferative disorders in recipients of marrow
allografts. Immunol Rev 1997, 157:195-216
110. Yee C, Thompson J, Roche P, Byrd D, Lee P, Piepkorn M, Kenyon K,
Davis M, Riddell S, Greenberg P: Melanocyte destruction after
antigen-specific immunotherapy of melanoma: direct evi-
dence of t cell-mediated vitiligo. J Exp Med 2000, 192:1637-1644
111. Dudley M, Wunderlich J, Robbins P, Yang J, Hwu P, Schwartzentruber
D, Topalian S, Sherry R, Restifo N, Hubicki A, Robinson M, Raffeld M,
Duray P, Seipp C, Rogers-Freezer L, Morton K, Mavroukakis S, White
D, Rosenberg S: Cancer Regression and Autoimmunity in Pa-
tients After Clonal Repopulation with Antitumor Lym-
phocytes [epub ahead of print] [Record Supplied By
Publisher]. Science 2002, 10.1126/science.1076514:
112. Yee C, Riddell S, Greenberg P: In vivo tracking of tumor-specific
T cells. Curr Opin Immunol 2001, 13:141-146
113. Taniguchi T, Matsui H, Fujita T, Takaoka C, Kashima N, Yoshimoto R,
Hamuro J: Structure and expression of a cloned cDNA for hu-
man interleukin-2. Nature 1983, 302:305-310
114. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Etting-
hausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al: Obser-
vations on the systemic administration of autologous
lymphokine – activated killer cells and recombinant inter-
leukin-2 to patients with metastatic cancer. N Engl J Med 1985,
313:1485-1492
115. Rosenberg SA: Perspectives on the use of interleukin 2 in can-
cer treatment. The Cancer Journal 1997, 3(Supplement 1):S2-S6
116. Cantrell DA, Smith KA: The interleukin-2 T-cell system: a new
cell growth model. Science 1984, 224:1312-1316
117. Smith KA: Rational interleukin 2 therapy. Cancer Journal 1997,
3:S137-140
118. Smith K: Interleukin 2 Immunotherapy. In: Therapeutic Immunolo-
gy  (Edited by: Austen F, Burakoff S, Rosen F, Strom T) Malden, MA: Black-
well Science, Inc. 2001, 240-250
119. Robb RJ, Munck A, Smith KA: T cell growth factor receptors.
Quantitation, specificity, and biological relevance. J Exp Med
1981, 154:1455-1474
120. Leonard WJ, Depper JM, Uchiyama T, Smith KA, Waldmann TA,
Greene WC: A monoclonal antibody that appears to recog-
nize the receptor for human T-cell growth factor; partial
characterization of the receptor. Nature 1982, 300:267-269
121. Sharon M, Klausner RD, Cullen BR, Chizzonite R, Leonard WJ: Novel
interleukin-2 receptor subunit detected by cross-linking un-
der high affinity conditions. Science 1986, 234:859-863
122. Teshigawara K, Wang HM, Kato K, Smith KA: Interleukin 2 high-
affinity receptor expression requires two distinct binding
proteins. J Exp Med 1987, 165:223-238
123. Takeshita T, Ohtani K, Asao H, Kumaki S, Nakamura M, Sugamura K:
An associated molecule, p64, with IL-2 receptor beta chain.
Its possible involvement in the formation of the functional in-
termediate – affinity IL-2 receptor complex. J Immunol 1992,
148:2154-2158
124. Waldmann TA, O'Shea J: The use of antibodies against the IL-2
receptor in transplantation. Curr Opin Immunol 1998, 10:507-512
125. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran
P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J:
Interleukin-2-receptor blockade with daclizumab to prevent
acute rejection in renal transplantation. Daclizumab Triple
Therapy Study Group. N Engl J Med 1998, 338:161-165
126. Beniaminovitz A, Itescu S, Lietz K, Donovan M, Burke E, Groff B, Ed-
wards N, Mancini D: Prevention of rejection in cardiac trans-
plantation by blockade of the interleukin-2 receptor with a
monoclonal antibody. N Engl J Med 2000, 342:613-619
127. Moreland L, Baumgartner S, Schiff M, et al: Treatment of rheuma-
toid arthritis with a recombinant tumor necrosis factor re-
ceptor (p75)-Fc fusion protein. N Eng J Med 1997, 337:141-147
128. Takeshita T, Asao H, Ohtani K, Ishii N, Kumaki S, Tanaka N, Manukata
H, Nakamura M, Sugamura K: Cloning of the Gamma chain of
the Human IL2 receptor. Science 1992, 257:379-382
129. Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi
WS, McBride OW, Leonard WJ: Interleukin 2 receptor gamma
chain mutation results in X-linked severe combined immun-
odeficiency in humans. Cell 1993, 73:147-157
130. Leonard W, Shores E, Love P: Role of the common cytokine re-
ceptor gamma chain in cytokine signaling and lymphoid de-
velopment. Immunol Rev 1995, 148:97-114
131. Cavazzana-Calvo M, Hacein-Bey S, de SBG, Gross F, Yvon E, Nus-
baum P, Selz F, Hue C, Certain S, Casanova J, Bousso P, Deist F,
Fischer A: Gene therapy of human severe combined immun-
odeficiency (SCID)-X1 disease. Science 2000, 288:669-672
132. Gillis S, Crabtree GR, Smith KA: Glucocorticoid-induced inhibi-
tion of T cell growth factor production. I. The effect on mi-
togen-induced lymphocyte proliferation. J Immunol 1979,
123:1624-1631
133. Yang-Yen H-F, Chambard J-C, Sun Y-L, Smeal T, Schmidt TJ, Drouin
J, Karin M: Transcriptional inteference between c-Jun and the
glucocorticoid receptor: mutual inhibition of DNA bindingPage 14 of 17
(page number not for citation purposes)
Medical Immunology  2002, 1 http://www.medimmunol.com/content/1/1/1due to direct protein-protein interaction. Cell 1990, 62:1205-
1215
134. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M: Immu-
nosupression by glucocorticoids: Inhibition of NFkB activity
through induction of IkB synthesis. Science 1995, 270:286-290
135. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS: Role of tran-
scriptional activation of IkB-alpha in mediation of immuno-
supression by glucocorticoids. Science 1995, 270:283-286
136. Bunjes D, Hardt C, Rollinghoff M, Wagner H: Cyclosporin A medi-
ates immunosuppression of primary cytotoxic T cell re-
sponses by impairing the release of interleukin 1 and
interleukin 2. Eur J Immunol 1981, 11:657-661
137. Northrop JP, Ho SN, Chen L, Thomas DJ, Timmerman LA, Nolan GP,
Admon A, Crabtree GR: NF-AT components define a family of
transcription factors targeted in T ell activation. Nature 1994,
369:497-502
138. Grigoriadis G, Zhan Y, Grumont R, Metcalf D, Handman E, Cheers C,
Gerondakis S: The Rel subunit of NF-kappaB-like transcription
factors is a positive and negative regulator of macrophage
gene expression: distinct roles for Rel in different macro-
phage populations. EMBO J 1996, 15:7099-7107
139. Tumang J, Owyang A, Andjelic S, Jin Z, Hardy R, Liou M, Liou H: c-
Rel is essential for B lymphocyte survival and cell cycle pro-
gression. Eur J Immunol 1998, 28:4299-4312
140. Liou H, Jin Z, Tumang J, Andjelic S, Smith K, Liou M: c-Rel is crucial
for lymphocyte proliferation but dispensable for T cell effec-
tor function. Int Immunol 1999, 11:361-371
141. Hsia C, Cheng S, Owyang A, Dowdy S, Liou H: c-Rel regulation of
the cell cycle in primary mouse B lymphocytes [In Process
Citation]. Int Immunol 2002, 14:905-916
142. Grumont R, Rourke I, O'Reilly L, Strasser A, Miyake K, Sha W,
Gerondakis S: B lymphocytes differentially use the Rel and nu-
clear factor kappaB1 (NF-kappaB1) transcription factors to
regulate cell cycle progression and apoptosis in quiescent
and mitogen-activated cells. J Exp Med 1998, 187:663-674
143. Sen R, Baltimore D: Inducibility of kappa immunoglobulin en-
hancer-binding protein Nf-kappa B by a posttranslational
mechanism. Cell 1986, 47:921-928
144. Shapiro A, Lakey J, Ryan E, Korbutt G, Toth E, Warnock G, Kneteman
N, Rajotte R: Islet transplantation in seven patients with type
1 diabetes mellitus using a glucocorticoid-free immunosup-
pressive regimen. N Engl J Med 2000, 343:230-238
145. Fu X, Kessler D, Veals S, Levy D, Darnell J: ISGF3, the transcrip-
tional activator induced by interferon alpha, consists of mul-
tiple interacting polypeptide chains. Proc Natl Acad Sci U S A
1990, 87:8555-8559
146. Darnell J, Kerr I, Stark G: Jak-STAT pathways and transcription-
al activation in response to IFNs and other extracellular sig-
naling proteins. Science 1994, 264:1415-1421
147. Brivanlou A, Darnell J: Signal transduction and the control of
gene expression. Science 2002, 295:813-818
148. O'Shea J, Gadina M, Schreiber R: Cytokine signaling in 2002: new
surprises in the Jak/Stat pathway. Cell 2002, 109(Suppl):S121-
131
149. Witthuhn B, Quelle F, Silvennoinen O, Yi T, Tang B, Miura O, Ihle J:
JAK2 associates with the erythropoietin receptor and is ty-
rosine phosphorylated and activated following stimulation
with erythropoietin. Cell 1993, 74:227-236
150. Ihle J: The Janus protein tyrosine kinase family and its role in
cytokine signaling. Adv Immunol 1995, 60:1-35
151. O'Shea J, Visconti R, Cheng T, Gadina M: Jaks and stats as thera-
peutic targets. Ann Rheum Dis 2000, 59(Suppl 1):i115-118
152. Schlossman S, Ben-Efraim S, Yaron A, Sober H: Immunochemical
studies on the antigenic determinants required to elicit de-
layed and immediate hypersensitivity reactions. J Exp Med
1966, 123:1083-1095
153. Unanue E, Askonas BA: Persistence of immunogenicity of anti-
gen after uptake by macrophages. J Exp Med 1968, 127:
154. Zeigler HK, Unanue ER: Decrease in macrophage antigen ca-
tabolism caused by ammonia and chloroquin is associated
with inhibition of antigen presentation to T cells. Proc Natl
Acad Sci USA 1982, 79:175-178
155. Mackaness G: The influence of immunologically committed
lymphoid cells on macrophage activity in vivo. J Exp Med 1969,
129:973-992
156. Nathan C, Karnovsky M, David J: Alterations of macrophage
functions by mediators from lymphocytes. J Exp Med 1971,
133:1356-1376
157. Nathan C, Remold H, David J: Characterization of a lymphocyte
factor which alters macrophage functions. J Exp Med 1973,
137:275-290
158. Lindahl P, Gresser I, Leary P, Tovey M: Enhanced expression of
histocompatibility antigens of lymphoid cells in mice treated
with interferon. J Infect Dis 1976, 133(Suppl):A66-68
159. Vignaux F, Gresser I: Differential effects of interferon on the ex-
pression of H-2K, H-2D, and Ia antigens on mouse lym-
phocytes. J Immunol 1977, 118:721-723
160. Nathan C, Murray H, Wiebe M, Rubin B: Identification of interfer-
on gamma as the lymphokne that activates human macro-
phage oxidative metabolism and antimicrobial activity. J Exp
Med 1983, 158:670-689
161. Murray H, Rubin B, Rothermal C: Killing of intracellular Leishma-
nia donovani by lymphokine-stimulated human mononu-
clear phagocytes: evidence that interferon-gamma is the
activating lymphokine. J Clin Invest 1983, 72:1506-1510
162. Babbitt B, Allen P, Matsueda G, Haber E, Unanue E: Binding of im-
munogenic peptides to Ia histocompatibility molecules. Na-
ture 1985, 317:359-361
163. Bjorkman PJ, Saper MA, Samaoui B, Bennett WS, Strominger JL, Wiley
DC: Structure of the human class I histocompatability anti-
gen, HLA-A2. Nature 1987, 329:506-511
164. Davis M, Bjorkman P: T cell antigen receptor genes and T cell
recognition. Nature 1988, 334:395-402
165. Reinherz EL, Schlossman SF: The differentiation and function of
T lymphocytes. Cell 1980, 4:821-827
166. Scollay R, Bartlett P, Shortman K: T cell development in the adult
murine thymus: changes in the expression of the surface an-
tigens Ly2, L3T4 and B2A2 during development from early
precursor cells to emigrants. Immunol Rev 1984, 82:79-103
167. Scollay R, Shortman K: Identification of early stages of T lym-
phocyte development in the thymus cortex and medulla. J Im-
munol 1985, 134:3632-3642
168. Kruisbeek A, Fultz M, Sharrow S, Singer A, Mond J: Early develop-
ment of the T cell repertoire. In vivo treatment of neonatal
mice with anti-Ia antibodies interferes with differentiation of
I-restricted T cells but not K/D-restricted T cells. J Exp Med
1983, 157:1932-1946
169. Kruisbeek A, Mond J, Fowlkes B, Carmen J, Bridges S, Longo D: Ab-
sence of the Lyt-2-, L3T4+ lineage of T cells in mice treated
neonatally with anti-I-A correlates with absence of intrath-
ymic I-A-bearing antigen-presenting cell function. J Exp Med
1985, 161:1029-1047
170. Kisielow P, Teh H, Bluthmann H, van Boehmer H: Positive selec-
tion of antigen-specific T cells in thymus by restricting MHC
molecules. Nature 1988, 335:730-733
171. Teh H, Kisielow P, Scott B, Kishi H, Uematsu Y, Bluthmann H, van
Boehmer H: Thymic major histocompatibility complex anti-
gens and the alpha beta T-cell receptor determine the CD4/
CD8 phenotype of T cells. Nature 1988, 335:229-233
172. Kisielow P, Bluthmann H, Staerz U, Steinmetz M, van Boehmer H:
Tolerance in T-cell-receptor transgenic mice involves dele-
tion of nonmature CD4+8+ thymocytes. Nature 1988, 333:742-
746
173. Oettinger M, Schatz D, Gorka C, Baltimore D: RAG-1 and RAG-2,
adjacent genes that synergistically activate V(D)J recombi-
nation. Science 1990, 248:1517-1523
174. Namen A, Lupton S, Hjerrild K, Wignall J, Mochizuki D, Schmierer A,
Mosley B, March C, Urdal D, Gillis S: Stimulation of B-cell pro-
genitors by cloned murine interleukin-7. Nature 1988, 333:571-
573
175. Mackall C, Fry T, Bare C, Morgan P, Galbraith A, Gress R: IL-7 in-
creases both thymic-dependent and thymic-independent T-
cell regeneration after bone marrow transplantation. Blood
2001, 97:1491-1497
176. Fry T, Christensen B, Komschlies K, Gress R, Mackall C: Inter-
leukin-7 restores immunity in athymic T-cell-depleted hosts.
Blood 2001, 97:1525-1533
177. Fry T, Mackall C: Interleukin-7: from bench to clinic. Blood 2002,
99:3892-3904Page 15 of 17
(page number not for citation purposes)
Medical Immunology  2002, 1 http://www.medimmunol.com/content/1/1/1178. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J: GM-CSF
and TNF-alpha cooperate in the generation of dendritic
Langerhan's cells. Nature 1992, 360:258-261
179. Inaba K, Steinman R, Pack M, Aya H, Inaba T, Sudoo S, Wolpe S, Schul-
er G: Identification of proliferating dendritic cells in mouse
blood. J Exp Med 1992, 175:1157-1167
180. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B,
Konwalinka G, Fritsch P, Steinman R, Schuler G: Proliferating den-
tritic cell progenitors in human blood. J Exp Med 1994, 180:83-
93
181. Sallusto F, Lanzavecchia A: Efficient presentation of soluble anti-
gen by cultured human dendritic cells is maintained by gran-
ulocyte/macrophage colony-stimulating factor plus
interleukin 4 and downregulated by tumor necrosis factor al-
pha. J Exp Med 1994, 179:1109-1118
182. Sallusto F, Cella M, Danieli C, Lanzavecchia A: Dendritic cells use
macropinocytosis and the mannose receptor to concentrate
macromolecules in the major histocompatibility complex
class II compartment: downregulation by cytokines and bac-
terial products. J Exp Med 1995, 182:389-400
183. Winzler C, Rovere P, Rescigno M, Granucci F, Penna G, Adorini L,
Zimmermann V, Davoust J, Ricciardi-Castagnoli P: Maturation stag-
es of mouse dendritic cells in growth factor-dependent long-
term cultures. J Exp Med 1997, 185:317-328
184. Maurer T, Heit A, Hochrein H, Ampenberger F, O'Keeffe M, Bauer S,
Lipford G, Vabulas R, Wagner H: CpG-DNA aided cross-presen-
tation of soluble antigens by dendritic cells [In Process Cita-
tion]. Eur J Immunol 2002, 32:2356-2364
185. Buelens C, Verhasselt V, De GD, Thielemans K, Goldman M, Willems
F: Human dendritic cell responses to lipopolysaccharide and
CD40 ligation are differentially regulated by interleukin-10.
Eur J Immunol 1997, 27:1848-1852
186. Siegal F, Kadowaki N, Shodell S, Fitzgerald-Bocarsly P, Shah K, Ho S,
Antonenko S, Liu Y-j: The nature of the principle interferon-
producing cells in human blood. Science 1999, 1835-1837
187. Banchereau J, Schuler-Thurner B, Palucka A, Schuler G: Dendritic
cells as vectors for therapy. Cell 2001, 106:271-274
188. Berger T, Feuerstein B, Strasser E, Hirsch U, Schreiner D, Schuler G,
Schuler-Thurner B: Large-scale generation of mature mono-
cyte-derived dendritic cells for clinical application in cell fac-
tories [In Process Citation]. J Immunol Methods 2002, 268:131
189. Banchereau J, de Paoli P, Valle A, Garcia E, Rousset F: Long-term
human B cell lines dependent on interleukin-4 and antibody
to CD40. Science 1991, 251:70-72
190. Banchereau J, Rouset F: Growing human B lymphocytes in the
CD40 system. Nature 1991, 353:678-679
191. Lederman S, Yellin M, Krichevsky A, Belko J, Lee J, Chess L: Identifi-
cation of a novel surface protein on activated CD4+ T cells
that induces contact-dependent B cell differentiation (help).
J Exp Med 1992, 175:1091-1099
192. Lederman S, Yellin MJ, Inghirami G, Lee JJ, Knowels DM, Chess L: Mo-
lecular interactions mediating T-B lymphocyte collaboration
in human lymphoid follicles. Roles of T cell-B cell activating
molecules (5c8 antigen) and CD40 in contact-dependent
help. J Immunol 1992, 149:3817-3826
193. Fuleihan R, Ramesh N, Loh R, Jabara H, Rosen R, Chatila T, Fu S, Sta-
menkovic I, Geha R: Defective expression of the CD40 ligand in
X chromosome-linked immunoglobulin deficiency with nor-
mal or elevated IgM. Proc Natl Acad Sci U S A 1993, 90:2170-2173
194. Papavasiliou F, Schatz D: Somatic hypermutation of immu-
noglobulin genes: merging mechanisms for genetic diversity.
Cell 2002, 109(suppl):35-44
195. Stavnezer J: Antibody class switching. Adv immunol 1996, 61:79-
146
196. Zan H, Cerutti A, Dramitinos P, Schaffer A, Li Z, Casali P: Induction
of Ig somatic hypermutation and class switching in a human
monoclonal IgM+ IgD+ B cell line in vitro: definition of the
requirements and modalities of hypermutation. J Immunol
1999, 162:3437-3447
197. Cerutti A, Zan H, Schaffer A, Bergsagel L, Harindranath N, Max E,
Casali P: CD40 ligand and appropriate cytokines induce
switching to IgG, IgA, and IgE and coordinated germinal
center and plasmacytoid phenotypic differentiation in a hu-
man monoclonal IgM+IgD+ B cell line. J Immunol 1998,
160:2145-2157
198. Litinskiy M, Nardelli B, Hilbert D, He B, Schaffer A, Casali P, Cerutti
A: DCs induce CD40-independent immunoglobulin class
switching through BLyS and APRIL. Nat Immunol 2002, 3:822-
829
199. Balazs M, Martin F, Zhou T, Kearney J: Blood dendritic cells inter-
act with splenic marginal zone B cells to initiate T-independ-
ent immune responses. Immunity 2002, 17:341-352
200. Poltorak A, He X, Smirnova I, Liu M, Huffel C, Du X, Birdwell D, Ale-
jos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Lay-
ton B, Beutler B: Defective LPS signaling in C3H/HeJ and
C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998,
282:2085-2088
201. Carswell E, Old L, Kassel R, Green S, Fiore N, Williamson B: An en-
dotoxin-induced serum factor that causes necrosis of tu-
mors. Proc Natl Acad Sci U S A 1975, 72:3666-3670
202. Kawakami M, Cerami A: Studies of endotoxin-induced decrease
in lipoprotein lipase activity. J Exp Med 1981, 154:631-639
203. Pennica D, Hayflick J, Bringman T, Palladino M, Goeddel D: Cloning
and expression in Escherichia coli of the cDNA for murine
tumor necrosis factor. Proc Natl Acad Sci U S A 1985, 82:6060-6064
204. Beutler B, Mahoney J, Le TN, Pekala P, Cerami A: Purification of ca-
chectin, a lipoprotein lipase-suppressing hormone secreted
by endotoxin-induced RAW 264.7 cells. J Exp Med 1985,
161:984-995
205. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumo-
to M, Hoshino K, Wagner H, Takeda K, Akira S: A Toll-like recep-
tor recognizes bacterial DNA. Nature 2000, 408:740-745
206. Alexopoulou L, Holt A, Medzhitov R, Flavell R: Recognition of dou-
ble-stranded RNA and activation of NF-kappaB by Toll-like
receptor 3. Nature 2001, 413:732-738
207. Garboczi D, Ghosh P, Utz U, Fan Q, Biddeson W, Wily D: Structure
of the complex between human T cell receptor, viral peptide
and HLA-A2. Nature 1996, 384:134-141
208. Garcia K, Degano M, Stanfield R, Brumark A, Jackson M, Peterson P,
Teyton L, Wilson I: An alpha/beta T cell recptor structure at
2.5 A and its orientation in the TCR-MHC complex. Science
1996, 274:209-219
209. Reinherz E, Tan K, Tang L, Kern P, Liu J, Xiong Y, Hussey R, Smolyar
A, Hare B, Zhang R, et al: The crystal structure of a T cell recp-
tor in complex with peptide and MHC Class II. Science 1999,
286:1913-1921
210. Wang J-H, Reinherz E: Structural basis of T cell recognition of
peptides bound to MHC molecules. Mol Immunol 2002, 38:1039-
1049
211. Altman JD, Moss PAH, Goulder PJR, Barouch DH, McHeyzer-Wil-
liams MG, Bell JI, McMichael AJ, Davis MM: Phenotypic analysis of
antigen-specific T lymphocytes. Science 1996, 274:94-96
212. Kern F, Surel I, Brock C, Freistedt B, Radtke H, Scheffold A, Blasczyk
R, Reinke P, Schneider-Mergener J, Radbruch A, Walden P, Volk H:
T-cell epitope mapping by flow cytometry. Nat Med 1998,
4:975-978
213. Kern F, Faulhaber N, Frommel C, Khatamzas E, Prosch S, Schone-
mann C, Kretzschmar I, Volkmer-Engert R, Volk H, Reinke P: Anal-
ysis of CD8 T cell reactivity to cytomegalovirus using
protein-spanning pools of overlapping pentadecapeptides.
Eur J Immunol 2000, 30:1676-1682
214. Maecker H, Dunn H, Suni M, Khatamzas E, Pitcher C, Bunde T, Per-
saud N, Trigona W, Fu T, Sinclair E, Bredt B, McCune J, Maino V, Kern
F, Picker L: Use of overlapping peptide mixtures as antigens
for cytokine flow cytometry. J Immunol Methods 2001, 255:27-40
215. Grakoui A, Bromley S, Sumen C, Davis M, Shaw A, Allen P, Dustin M:
The immunological synapse: a molecular machine control-
ling T cell activation. Science 1999, 285:221-227
216. Sylvestre D, Ravetch J: Fc receptors initiate the Arthus reac-
tion: redefining the inflammatory cascade. Science 1994,
265:1095-1098
217. Sylvestre D, Ravetch J: A dominant role for mast cell Fc recep-
tors in the Arthus reaction. Immunity 1996, 5:387-390
218. Sylvestre D, Clynes R, Ma M, Warren H, Carroll M, Ravetch J: Immu-
noglobulin G-mediated inflammatory responses develop
normally in complement-deficient mice. J Exp Med 1996,
184:2385-2392
219. Ravetch J, Clynes R: Divergent roles for Fc receptors and com-
plement in vivo. Annu Rev Immunol 1998, 16:421-432
220. Ujike A, Ishikawa Y, Ono M, Yuasa T, Yoshino T, Fukumoto M,
Ravetch J, Takai T: Modulation of immunoglobulin (Ig)E-medi-Page 16 of 17
(page number not for citation purposes)
Medical Immunology  2002, 1 http://www.medimmunol.com/content/1/1/1ated systemic anaphylaxis by low-affinity Fc receptors for
IgG. J Exp Med 1999, 189:1573-1579
221. Clynes R, Maizes J, Guinamard R, Ono M, Takai T, Ravetch J: Modu-
lation of immune complex-induced inflammation in vivo by
the coordinate expression of activation and inhibitory Fc re-
ceptors. J Exp Med 1999, 189:179-185
222. Cochran B, Reffel A, Stiles C: Molecular cloning of a set of genes
sequences regulated by platelet-derived growth factor. Cell
1983, 33:939-947
223. Beadling C, Johnson KW, Smith KA: Isolation of interleukin 2-in-
duced immediate-early genes. Proc Natl Acad Sci U S A 1993,
90:2719-2723
224. Herbolt S, Chastagner P, Samady L, Moreau J-L, Demaison C, Frous-
sard P, Liu X, Bonnet J, Theze J: IL2-dependent expression of
genes involved in cytoskeleton organization, oncogene regu-
lation and transcriptional control. J Immunol 1999, 162:3280-
3288
225. Ehlers S, Benini J, Held H, Roeck C, Alber G, Uhlig S: Alpha-beta T
cell receptor-positive cells and interferon-gamma, but not
inducible nitric oxide synthase, are critical for granuloma
necrosis in a mouse model of mycobacteria-induced pulmo-
nary immunopathology. J Exp Med 2001, 194:1847-1859
226. Paoletti E, Tartaglia J, Taylor J: Safe and effective poxvirus vec-
tors – NYVAC and ALVAC. Dev Biol Stand 1994, 82:65-69
227. Plotkin S, Cadoz M, Meignier B, Meric C, Leroy O, Excler J, Tartaglia
J, Paoletti E, Gonczol E, Chappuis G: The safety and use of canary-
pox vectored vaccines. Dev Biol Stand 1995, 84:165-170
228. Ferrari G, Berend C, Ottinger J, Dodge R, Bartlett J, Toso J, Moody
D, Tartaglia J, Cox W, Paoletti E, Weinhold K: Replication-defec-
tive canarypox (ALVAC) vectors effectively activate anti-hu-
man immunodeficiency virus-1 cytotoxic T lymphocytes
present in infected patients: implications for antigen-specific
immunotherapy. Blood 1997, 90:2406-2416
229. Clements-Mann M, Weinhold K, Matthews T, Graham B, Gorse G,
Keefer M, McElrath M, Hsieh R, Mestecky J, Zolla-Pazner S, Mascola
J, Schwartz D, Siliciano R, Corey L, Wright P, Belshe R, Dolin R, Jack-
son S, Xu S, Fast P, Walker M, Stablein D, Excler J, Tartaglia J, Paoletti
E, et al: Immune responses to human immunodeficiency virus
(HIV) type 1 induced by canarypox expressing HIV-1MN
gp120, HIV-1SF2 recombinant gp120, or both vaccines in se-
ronegative adults. NIAID AIDS Vaccine Evaluation Group. J
Infect Dis 1998, 177:1230-1246
Publish with BioMed Central  and  every 
scientist can read your work free of charge
"BioMedcentral will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Paul Nurse, Director-General, Imperial Cancer Research Fund
Publish with BMC and your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours - you keep the copyright
editorial@biomedcentral.com
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/
BioMedcentral.comPage 17 of 17
(page number not for citation purposes)
